Reproductive system disorder
MONDO:0005039A disease involving the reproductive system.
Also known as: disease of reproductive system, disease or disorder of reproductive system, disorder of reproductive system, genital disorders, reproductive disease, reproductive system disease, reproductive system disease or disorder, reproductive system disorder
8533 clinical trials for this condition and its sub-types, 15 tagged with Reproductive system disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Reproductive system disorder
-
Reproductive system neoplasm 0 trials · 4,651 incl. sub-types
9 sub-types
- Reproductive system cancer 4 trials · 4,380 incl. sub-types Sub-types →
- Female reproductive system neoplasm 27 trials · 2,428 incl. sub-types Sub-types →
- Male reproductive system neoplasm 1 trial · 2,370 incl. sub-types Sub-types →
- Prostate neoplasm 124 trials · 2,225 incl. sub-types Sub-types →
- Benign reproductive system neoplasm 0 trials · 117 incl. sub-types Sub-types →
- Pituitary tumor 23 trials · 83 incl. sub-types Sub-types →
- Sex cord-stromal tumor 4 trials · 14 incl. sub-types Sub-types →
- Brenner tumor 6 trials Sub-types →
- Gonadal tissue neoplasm 0 trials
-
Female reproductive system disorder 27 trials · 3,567 incl. sub-types
34 sub-types
- Female reproductive system neoplasm 27 trials · 2,428 incl. sub-types Sub-types →
- Uterine disorder 18 trials · 1,919 incl. sub-types Sub-types →
- Ovarian disorder 10 trials · 1,388 incl. sub-types Sub-types →
- Fallopian tube disorder 5 trials · 428 incl. sub-types Sub-types →
- Menstrual disorder 16 trials · 191 incl. sub-types Sub-types →
- Vaginal disorder 3 trials · 172 incl. sub-types Sub-types →
- Female infertility 107 trials · 161 incl. sub-types Sub-types →
- Vulvar disease 8 trials · 154 incl. sub-types Sub-types →
- Preterm premature rupture of the membranes 35 trials
- Prolapse of female genital organ 32 trials · 35 incl. sub-types Sub-types →
- Asherman syndrome 19 trials
- Gynatresia 18 trials
- Vulvodynia 18 trials
- Ectopic pregnancy 15 trials Sub-types →
- Pelvic inflammatory disease 4 trials · 14 incl. sub-types Sub-types →
- Mullerian aplasia 9 trials · 10 incl. sub-types Sub-types →
- Granulomatous mastitis 6 trials
- Delayed puberty, self-limited 3 trials
- Allen-Masters syndrome 0 trials
- Bartholin duct cyst 0 trials
- Bartholin's gland disease 0 trials
- Endosalpingiosis 0 trials Sub-types →
- Hymen, imperforate 0 trials
- Isolated partial vaginal agenesis 0 trials
- Longitudinal vaginal septum 0 trials
- Mammary-digital-nail syndrome 0 trials
- Menstrual cycle-dependent periodic fever 0 trials
- Polycystic ovaries-urethral sphincter dysfunction syndrome 0 trials
- Polyp of vulva 0 trials Sub-types →
- Transverse vaginal septum 0 trials
- Uterine cervical aplasia and agenesis 0 trials
- Vaginal atresia 0 trials
- Vulval varices 0 trials
- Vulvovaginal gingival syndrome 0 trials
-
Male reproductive system disorder 11 trials · 2,826 incl. sub-types
26 sub-types
- Prostate disorder 16 trials · 2,439 incl. sub-types Sub-types →
- Male reproductive system neoplasm 1 trial · 2,370 incl. sub-types Sub-types →
- Penile disorder 3 trials · 194 incl. sub-types Sub-types →
- Testicular disorder 2 trials · 111 incl. sub-types Sub-types →
- Male infertility 74 trials · 92 incl. sub-types Sub-types →
- Scrotal disorder 2 trials · 19 incl. sub-types Sub-types →
- Cryptorchidism 14 trials Sub-types →
- Hydrocele 6 trials Sub-types →
- Epididymitis 2 trials Sub-types →
- Fournier gangrene 2 trials
- Congenital bilateral absence of vas deferens 1 trial Sub-types →
- Hematocele of tunica vaginalis testis 1 trial
- Isolated micropenis 1 trial
- Spermatocele 1 trial
- Benign male reproductive system neoplasm 0 trials Sub-types →
- Congenital agenesis of the scrotum 0 trials
- Congenital megaprepuce 0 trials
- Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome 0 trials
- Diphallia 0 trials
- Epididymis disease 0 trials
- Male genital organ stricture 0 trials
- Male genital organ vascular disease 0 trials
- Male genital tuberculosis 0 trials Sub-types →
- Penoscrotal transposition 0 trials
- Posterior hypospadias 0 trials
- Postorgasmic illness syndrome 0 trials
-
Sexually transmitted disease 127 trials · 1,703 incl. sub-types
3 sub-types
- Viral sexually transmitted disease 5 trials · 1,589 incl. sub-types Sub-types →
- Bacterial sexually transmitted disease 8 trials · 113 incl. sub-types Sub-types →
- Trichomonas vaginitis urogenital infection 7 trials Sub-types →
-
Gonadal disorder 3 trials · 1,635 incl. sub-types
6 sub-types
- Ovarian disorder 10 trials · 1,388 incl. sub-types Sub-types →
- Hypogonadism 47 trials · 163 incl. sub-types Sub-types →
- Testicular disorder 2 trials · 111 incl. sub-types Sub-types →
- Disorder of sexual differentiation 9 trials · 53 incl. sub-types Sub-types →
- Precocious puberty 18 trials · 19 incl. sub-types Sub-types →
- Gonadoblastoma 0 trials Sub-types →
-
Infertility disorder 361 trials · 544 incl. sub-types
5 sub-types
- Female infertility 107 trials · 161 incl. sub-types Sub-types →
- Male infertility 74 trials · 92 incl. sub-types Sub-types →
- Pregnancy loss, recurrent, 4 14 trials
- SYCE1-related gametogenic failure 0 trials Sub-types →
- Inherited oocyte maturation defect 0 trials Sub-types →
-
Physiological sexual disorder 78 trials · 197 incl. sub-types
1 sub-type
- Erectile dysfunction 121 trials · 125 incl. sub-types Sub-types →
-
Pituitary gland disorder 18 trials · 175 incl. sub-types
9 sub-types
- Pituitary tumor 23 trials · 83 incl. sub-types Sub-types →
- Anterior pituitary gland disorder 1 trial · 60 incl. sub-types Sub-types →
- Hypopituitarism 5 trials · 46 incl. sub-types Sub-types →
- Neurohypophyseal diabetes insipidus 9 trials
- Inappropriate ADH syndrome 5 trials
- Hypophysitis 2 trials Sub-types →
- Necrosis of pituitary 0 trials · 1 incl. sub-types Sub-types →
- Empty sella syndrome 0 trials
- Pituitary hypoplasia 0 trials
-
Pelvic organ prolapse 125 trials
-
Dysplasia of cervix 55 trials · 105 incl. sub-types
1 sub-type
- Cervical intraepithelial neoplasia 75 trials · 104 incl. sub-types Sub-types →
-
Hypospadias 35 trials
5 sub-types
- Hypospadias 1, X-linked 0 trials
- Hypospadias 2, X-linked 0 trials
- Hypospadias 3, autosomal 0 trials
- Hypospadias 4, X-linked 0 trials
- Isolated female hypospadias 0 trials
-
Habitual spontaneous abortion 28 trials
-
Currarino triad 1 trial
-
4 sub-types
- 46,XX sex reversal 4 0 trials
- 46,XY sex reversal 3 0 trials
- Premature ovarian failure 7 0 trials
- Spermatogenic failure 8 0 trials
-
Aromatase excess syndrome 0 trials
-
Cortisone reductase deficiency 0 trials
2 sub-types
- Cortisone reductase deficiency 1 0 trials
- Cortisone reductase deficiency 2 0 trials
-
Diethylstilbestrol syndrome 0 trials
-
Estrogen resistance syndrome 0 trials
-
Female genital tuberculosis 0 trials
-
Hand-foot-genital syndrome 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 3221 trials in this tab.
-
Can aggressive prostate cancer treatment extend life in men over 75?
Cure Recruiting nowResearchers are testing whether immediate curative treatment (surgery or radiotherapy, with or without hormone therapy) helps men aged 75 and older with high-risk, non-metastatic prostate cancer live longer and with better quality of life compared to conservative, symptom-focused…
Phase 3 • Sponsor: Sven Löffeler • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Electric pulses target prostate tumors while sparing healthy tissue
Cure Recruiting nowResearchers are testing a procedure called irreversible electroporation in men with localized prostate cancer. The technique uses electrical pulses to destroy cancer cells in the prostate while aiming to avoid damage to nearby nerves and structures. The study will follow 10 men f…
Sponsor: Chinese University of Hong Kong • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
New HIV vaccine booster trial launches: could it strengthen immunity?
Vaccine Recruiting nowThis early-stage trial is testing a new HIV vaccine booster called VRIPRO, given with an immune-boosting adjuvant, in 40 healthy adults aged 18-60 who previously received an HIV vaccine in the HVTN 706 study. Participants will get three shots over 24 weeks. The main goals are to …
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 20, 2026 00:00 UTC
-
New mRNA HIV vaccines enter early human testing
Vaccine Recruiting nowThis early-stage trial will test two experimental mRNA vaccines designed to teach the immune system to make antibodies that target HIV. About 42 adults with well-controlled HIV will receive the vaccines and then temporarily pause their regular HIV medication under close monitorin…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 16, 2026 00:00 UTC
-
Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread
Disease control Recruiting nowThis phase II trial tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy, with or without additional hormone-blocking pills, can better control low-volume metastatic hormone-sensitive prostate cancer. The study enrolls men whose cancer has s…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo aims to control Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new combination of two drugs (tulmimetostat and JSB462) in men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The trial has two parts: first, finding the safest dose, then comparing the combination to usual car…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for tough prostate cancer: Immune-Engaging drug enters human trials
Disease control Recruiting nowThis early-phase trial tests a new drug, GSK5458514, designed to help the immune system attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The study will first find a safe dos…
Phase 1/2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Poop pills? stool transplants may ease immunotherapy side effects
Disease control Recruiting nowThis early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …
Phase 1 • Sponsor: SHY Therapeutics • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New electric pulse therapy could replace radiation boost for prostate cancer
Disease control Recruiting nowThis study compares a new boost approach called irreversible electroporation (IRE) using the NanoKnife system against the standard radiation boost for men with intermediate-risk prostate cancer. All participants will receive standard stereotactic body radiation therapy (SBRT), bu…
Phase 3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can hormone patches and pills help teens with ovarian failure?
Disease control Recruiting nowThis study looks at how hormone replacement therapy (HRT) affects adolescents aged 11-19 with premature ovarian insufficiency (POI), a condition where ovaries stop working before age 40. Participants receive estrogen patches and progesterone pills over 2 years, with regular check…
Phase 3 • Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a new drug ASP388B take on advanced solid tumors?
Disease control Recruiting nowThis trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Targeted therapy boost for aggressive uterine cancer under study
Disease control Recruiting nowThis phase 3 trial tests whether adding targeted drugs (trastuzumab and pertuzumab) to standard chemotherapy can better shrink tumors in people with HER2-positive endometrial cancer. The study plans to enroll 360 participants with various stages of the disease. However, the trial…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody combo shows promise in early cancer trial
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…
Phase 1/2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for HIV patients with blood cancer: safer bone marrow transplants on the horizon?
Disease control Recruiting nowThis study tests whether a combination of three drugs (cyclophosphamide, bortezomib, and maraviroc) can safely prevent graft-versus-host disease after a half-matched bone marrow transplant in people living with HIV who also have a blood cancer. The trial involves 265 participants…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo targets tough prostate cancer
Disease control Recruiting nowThis study is testing a new drug called ADI-PEG20, which breaks down arginine (a nutrient cancer cells need), together with two chemotherapy drugs (carboplatin and cabazitaxel) in men with aggressive variant prostate cancer. The goal is to find the safest dose and check for side …
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug aims to supercharge immune system against prostate cancer
Disease control Recruiting nowThis phase II trial tests whether adding an experimental drug called PDS01ADC to standard radiation and hormone therapy can help the immune system fight prostate cancer. About 65 men with high- or intermediate-risk prostate cancer that hasn't spread will take part. Some will get …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for tough prostate cancer: BNT324 takes on chemo
Disease control Recruiting nowThis study tests a new drug called BNT324 against standard chemotherapy (docetaxel) in men with metastatic castration-resistant prostate cancer that has progressed after hormone therapy. The goal is to see if BNT324 helps patients live longer without their cancer worsening. About…
Phase 3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can daily adaptive radiotherapy spare healthy tissue in prostate cancer?
Disease control Recruiting nowResearchers are testing whether daily adaptive radiotherapy, which adjusts the radiation plan to each day's anatomy, causes fewer bladder and bowel side effects than standard radiotherapy in people with intermediate or high risk localized prostate cancer. The trial also compares …
Phase 2 • Sponsor: Scott Tyldesley • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug shows promise in slowing spread of aggressive prostate cancer
Disease control Recruiting nowThis study tests whether adding the drug saruparib to standard radiation and hormone therapy can delay the spread of cancer in 700 men with high-risk prostate cancer that has a BRCA gene mutation. Participants will receive either saruparib or a placebo alongside their usual treat…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Prison program aims to alert partners of HIV risk
Disease control Recruiting nowThis study tests whether a program that helps incarcerated men with HIV notify their sex and drug-use partners about possible HIV exposure can increase testing and treatment. Participants can choose to tell partners themselves or have a trained notifier do it anonymously. The goa…
Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for advanced penile cancer: drug combo targets tough cases
Disease control Recruiting nowThis study tests a new combination of two drugs (becotatug vedotin and pucotenlimab) in 20 adults with advanced penile cancer that has spread and is EGFR-positive. Participants must have failed or be unable to tolerate chemotherapy. The goal is to see if the treatment can shrink …
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Triple threat: new combo aims to tackle Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new drug, AMO959, combined with a targeted radiation therapy (Pluvicto) and a hormone therapy in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has stopped responding to prior hormone treatment. The trial has two phases: first t…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo aims to shrink HER2-Positive tumors
Disease control Recruiting nowThis study tests whether adding palbociclib to neratinib works better than neratinib alone for people with HER2-positive solid tumors (excluding breast cancer). Both drugs block signals that help cancer cells grow. The trial enrolls 70 adults with advanced or recurrent gynecologi…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a simpler HIV pill protect moms and babies?
Disease control Recruiting nowThis study will test a two-drug HIV pill (Dolutegravir/Lamivudine) in 210 pregnant women who have never taken HIV medication. The goal is to see if it controls the virus and prevents passing HIV to their babies. Participants will be compared to those on standard three-drug therap…
Phase 4 • Sponsor: Fundación Huésped • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Two-Drug combo targets prostate cancer that outsmarts hormone therapy
Disease control Recruiting nowResearchers are testing a combination of two experimental drugs, JANX013 and JANX007, in men with metastatic castration-resistant prostate cancer, an advanced form that keeps growing despite hormone-lowering treatment. The Phase 1 trial gives both drugs by intravenous infusion to…
Phase 1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…
Phase 1/2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a blast of testosterone shrink hard-to-treat prostate cancer?
Disease control Recruiting nowThis trial investigates whether high doses of testosterone can shrink tumors in men with metastatic prostate cancer that no longer responds to standard hormone therapy and has mutations in DNA repair genes like ATM or CDK12. Participants receive monthly injections of high-dose te…
Phase 2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Five-Fraction radiation plus hormone therapy tested against High-Risk prostate cancer
Disease control Recruiting nowResearchers are testing a treatment plan for men with high-risk localized prostate cancer that combines whole-pelvis radiation given in five sessions, a high-dose radiation boost directly to the prostate, and two years of androgen deprivation therapy. The study aims to see how of…
Phase 2 • Sponsor: German Oncology Center, Cyprus • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Precision radiation may tame prostate cancer with fewer side effects
Disease control Recruiting nowThis phase II trial is testing a focused, high-dose radiation therapy (SBRT) given in just two sessions for men with early-stage prostate cancer that hasn't spread. The goal is to see if this approach can destroy the tumor while avoiding the side effects of treating the whole pro…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Radioactive One-Two punch takes on returning prostate cancer
Disease control Recruiting nowThis phase II trial is testing two radioactive drugs, 225Ac-PSMA-617 and 177Lu-PSMA-617, combined with precise radiation therapy for prostate cancer that has returned and spread to a few spots in the body. The drugs target a protein on cancer cells and deliver radiation to kill t…
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo aims to keep ovarian cancer at bay
Disease control Recruiting nowThis Phase 3 trial tests whether a targeted therapy called sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer without their cancer growing. About 900 participants who have finished initial chemotherapy will…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New Triple-Drug attack on cervical cancer enters final testing
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (sac-TMT) to standard immunotherapy (pembrolizumab) and a targeted therapy (bevacizumab) helps people with metastatic cervical cancer live longer. About 1,000 participants whose cancer has sprea…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo takes on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new drug called ifinatamab deruxtecan (I-DXd), given alone or with other treatments, in men with metastatic castration-resistant prostate cancer (mCRPC) that has worsened despite hormone therapy. The trial aims to find safe doses and see if the drug can lower P…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Precision radiotherapy may buy time for men with spreading prostate cancer
Disease control Recruiting nowThis study investigates whether precisely targeted radiotherapy can delay the need for stronger drugs in men with prostate cancer that has started to grow in a few new spots while on systemic therapy. Participants have metastatic hormone-sensitive or castration-resistant prostate…
Sponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in large trial
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…
Phase 2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug cocktail targets Virus-Linked cancers in early trial
Disease control Recruiting nowThis phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kapo…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for endometrial cancer: targeted drug BNT323 faces chemo in phase 3 trial
Disease control Recruiting nowThis Phase 3 trial tests whether the drug BNT323 (trastuzumab pamirtecan) works better than standard chemotherapy for people with recurrent endometrial cancer that expresses HER2. About 480 participants will be split into two groups based on their HER2 levels. The study measures …
Phase 3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Which drug first? trial tests sequence of carboplatin and olaparib in aggressive prostate cancer
Disease control Recruiting nowResearchers are comparing two sequences of treatment for metastatic castration-resistant prostate cancer that carries certain DNA repair gene mutations. Participants receive either carboplatin first and olaparib second, or olaparib first and carboplatin second, switching after th…
Phase 2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for tough prostate cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard treatments (abiraterone or enzalutamide) in about 1,300 men with metastatic castration-resistant prostate cancer that got worse after one prior hormone therapy. The goal is to s…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Prostate cancer radiation in one day? new study tests faster treatment
Disease control Recruiting nowThis study tests a new way to deliver radiation therapy for early-stage prostate cancer. Instead of two separate sessions days apart, both radiation doses are given just three hours apart on the same day. The goal is to see if this is safe and could make treatment more convenient…
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug aims to control advanced cervical cancer
Disease control Recruiting nowThis phase 2 trial tests a drug called lorigerlimab (MGD019) in 47 people with advanced cervical cancer that has spread or come back. The goal is to see if the drug can help control the cancer and improve survival. Participants receive the drug through an IV. The study is current…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill combo aims to tame advanced prostate cancer
Disease control Recruiting nowThis study tests a new drug called HRS-5041, taken as a pill, combined with other cancer treatments for men with advanced prostate cancer. The goal is to see if the combination is safe and helps control the cancer. About 100 men aged 18 to 80 will take part. The study is currentl…
Phase 1/2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for Hard-to-Treat prostate cancer: experimental drug combo trial opens
Disease control Recruiting nowThis clinical trial is testing an experimental drug called opevesostat (MK-5684), either alone or combined with other cancer drugs, in people with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The study involves 220 participants and has t…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…
Phase 1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis early-stage study tests a new treatment for people with ovarian cancer that has come back. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack a protein (FSHR) found on cancer cells. The main goal is to check the safety of these…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug cocktail aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…
Phase 1/2 • Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for tough prostate cancer: targeted drug vs chemo in major trial
Disease control Recruiting nowThis study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It compares a new targeted drug, ifinatamab deruxtecan, to standard chemotherapy (docetaxel) to see which helps people live longer a…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for womb cancer: drug duo aims to slow tumor growth
Disease control Recruiting nowThis study tests whether adding sacituzumab tirumotecan (Sac-TMT) to pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without the cancer getting worse. About 1,100 participants with a specific type of endometrial cancer (pMMR) will receive eith…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a cancer drug flush out hidden HIV?
Disease control Recruiting nowResearchers are testing venetoclax, a drug that prompts certain cells to self-destruct, in people living with HIV who take antiretroviral therapy. The goal is to see if it can safely reduce the size of the latent HIV reservoir, the hidden pool of virus that persists despite treat…
Phase 1/2 • Sponsor: University of Aarhus • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could immature sperm cells help infertile men become fathers?
Disease control Recruiting nowThis study tests whether round spermatids (immature sperm cells) can be used in IVF to help men with a condition called non-obstructive azoospermia, where no mature sperm are present. Researchers will collect these cells from the testicles and inject them into eggs to see if they…
Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Immunotherapy duo shows promise for Tough-to-Treat uterine cancer
Disease control Recruiting nowThis phase II trial is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, works better than nivolumab alone for women with recurrent endometrial cancer that has a specific DNA repair defect (dMMR). About 81 participants will receive either the combinatio…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a smart drug missile take down a tough ovarian cancer?
Disease control Recruiting nowThis phase 2 trial is testing whether a targeted antibody-drug conjugate called sacituzumab tirumotecan, given alone or together with the immunotherapy pembrolizumab, can shrink tumors in people with ovarian clear cell carcinoma that has returned after prior immunotherapy. The st…
Phase 2 • Sponsor: Tufts Medical Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Shorter, personalized radiation may target endometrial cancer with fewer side effects
Disease control Recruiting nowResearchers are testing a shorter, adapted form of radiation therapy for people with high-risk endometrial cancer after surgery. The trial enrolls 20 patients and uses daily imaging to adjust the radiation plan to each person's anatomy. Participants receive moderately hypofractio…
Sponsor: Xiaorong Hou • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could a drink replace daily shots for growth hormone deficiency?
Disease control Recruiting nowThis study tests an oral medicine called GS3-007a for children with growth hormone deficiency. In the first part, kids receive different doses or a placebo for 14 days to check safety. In the second part, they take the chosen dose or a standard injection for 52 weeks to see how w…
Phase 1/2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for toddlers with rare hormone disorder?
Disease control Recruiting nowThis study tests a drug called crinecerfont in 20 children aged 3 months to 4 years with classic congenital adrenal hyperplasia (CAH). The goal is to see if the drug is safe and tolerable. Participants must already be on stable hydrocortisone treatment. The study is not yet recru…
Phase 2 • Sponsor: Neurocrine Switzerland GmbH • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a pill shrink Hard-to-Treat ovarian tumors?
Disease control Recruiting nowResearchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…
Phase 1/2 • Sponsor: Heronova Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…
Phase 1 • Sponsor: Accent Therapeutics • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill targets tough cancers with genetic flaw
Disease control Recruiting nowThis study tests an experimental oral drug, GSK5460025, alone or with other cancer drugs, in adults whose solid tumors have specific genetic changes (dMMR or MSI-H). The goal is to see if the drug can shrink tumors and to check its safety. About 47 people with advanced cancers th…
Phase 1/2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can inhaled manganese make ovarian cancer immunotherapy hit harder?
Disease control Recruiting nowResearchers are testing whether adding inhaled manganese chloride to standard chemotherapy and an anti-PD-1 immunotherapy can help people with advanced ovarian cancer that has worsened after at least two prior treatments. The trial enrolls about 120 participants and randomly assi…
Phase 3 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for rare cancers: Triple-Drug attack shows promise
Disease control Recruiting nowThis phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can an immunotherapy boost give advanced cervical cancer patients more time?
Disease control Recruiting nowResearchers are testing whether adding an experimental immunotherapy drug called GLS-010 to standard platinum-based chemotherapy, with or without bevacizumab, helps women with persistent, recurrent, or metastatic cervical cancer live longer. The trial enrolls about 424 women aged…
Phase 3 • Sponsor: Guangzhou Gloria Biosciences Co., Ltd. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug BL-M14D1 targets tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
DNA-Guided immunotherapy trial aims to match drug to tumor
Disease control Recruiting nowThis study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…
Phase 2 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Engineered immune cells take on Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis early-stage trial is testing a new treatment called GB-5267 for people with ovarian cancer that no longer responds to platinum-based chemotherapy. GB-5267 is a type of immune cell therapy (CAR T cell) that has been engineered to better target cancer cells and includes an ext…
Phase 1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for Hard-to-Treat prostate cancer? early trial launches
Disease control Recruiting nowThis early-phase trial is testing a new drug called GSK5471713 in 54 men with metastatic castration-resistant prostate cancer that has worsened despite standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors or lower PSA levels. It is the fir…
Phase 1/2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control Recruiting nowThis phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo aims to stall endometrial cancer in High-Risk patients
Disease control Recruiting nowThis study tests whether two drugs, abemaciclib and letrozole, can help keep advanced or recurrent endometrial cancer from getting worse. About 32 people with a specific type of estrogen-sensitive cancer will take these pills daily after initial treatment. The goal is to see if t…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill takes on brain tumors and metastases in early trial
Disease control Recruiting nowThis study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…
Phase 1/2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New gene therapy combo aims to boost ovarian cancer survival
Disease control Recruiting nowThis phase 3 trial tests whether adding a gene therapy called IMNN-001 (given into the abdomen) to standard chemotherapy helps people with advanced ovarian, fallopian tube, or peritoneal cancer live longer. About 500 newly diagnosed patients will be randomly assigned to receive e…
Phase 3 • Sponsor: Imunon • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a probiotic fight anal cancer in HIV patients?
Disease control Recruiting nowThis study tests whether a probiotic called EXE-346 can help treat anal high-grade squamous intraepithelial lesions (HSIL) and reduce persistent high-risk HPV infection in people living with HIV. The trial will enroll 90 participants who will take the probiotic or a placebo daily…
Phase 2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a natural pill prevent blood clots in ovarian cancer patients?
Disease control Recruiting nowThis study tests whether a daily pill called isoquercetin, made from a plant compound, can reduce blood markers linked to clot risk in people with ovarian cancer. About 90 participants receiving chemotherapy will take either isoquercetin or a placebo for up to 6 weeks. The goal i…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New male contraceptive device aims to be reversible
Disease control Recruiting nowThis study is testing a new device called Plan A that blocks sperm from passing through the vas deferens, similar to a vasectomy, but designed to be reversed later. Forty healthy men aged 25 to 65 will receive the device and be monitored for safety and effectiveness. The goal is …
Phase 2 • Sponsor: Next Life Sciences • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for hard-to-treat ovarian cancer: experimental drug targets key protein
Disease control Recruiting nowThis study tests a new drug called INCB123667 in 160 people with a type of ovarian cancer that no longer responds to platinum chemotherapy and has high levels of a protein called cyclin E1. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants…
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Hope for Platinum-Resistant ovarian cancer: new pill takes on chemo
Disease control Recruiting nowThis Phase 3 trial tests a new oral drug, INCB123667, against standard chemotherapy in 466 people with platinum-resistant ovarian cancer that overexpresses cyclin E1. The goal is to see if the new drug can delay cancer growth or improve survival. Participants will be randomly ass…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can some seminoma patients safely skip heavier treatment?
Disease control Recruiting nowThis phase 2 trial explores whether some people with stage II seminoma, a type of testicular cancer, can receive less intensive treatment after surgery. All participants first receive one cycle of EP chemotherapy. Those whose PET scan is negative are then randomly assigned to eit…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New radioactive drug takes aim at Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new drug that delivers radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has stopped responding to hormone therapy. The study will check for side effects and see if the drug …
Phase 1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-phase trial is testing a new drug called xaluritamig (AMG 509) in 40 adults with metastatic castration-resistant prostate cancer, a type that has spread and no longer responds to hormone therapy. The main goal is to check the drug's safety and how it moves through the …
Phase 1 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could less be more? new trial tailors endometrial cancer treatment to tumor type
Disease control Recruiting nowThis phase II study is testing whether women with certain types of early-stage endometrial cancer can safely receive less aggressive treatment after surgery. The approach is guided by the tumor's molecular profile—either POLE-mutated or p53 wildtype/NSMP. Around 393 participants …
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…
Phase 1/2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Immunotherapy before Chemo-Radiation shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing whether the immunotherapy drug dostarlimab (TSR-042), followed by standard chemoradiation and surgery, can effectively treat advanced mismatch repair deficient (dMMR) solid tumors. About 212 adults with locally advanced dMMR cancers will receive the drug int…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cell therapy trial hopes to tackle tough cancers
Disease control Recruiting nowThis early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…
Phase 1/2 • Sponsor: Second Life Therapeutics • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo aims to wipe out hidden ovarian cancer cells
Disease control Recruiting nowThis study tests whether adding the experimental drug IMNN-001 to standard chemotherapy and bevacizumab can better eliminate remaining cancer in people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. About 30 participants will be randomly assi…
Phase 1/2 • Sponsor: Imunon • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can blocking adenosine receptors help the immune system fight solid tumors?
Disease control Recruiting nowResearchers are testing two experimental oral drugs, TT-10 and TT-4, in adults with advanced solid tumors such as kidney, prostate, and lung cancers that have worsened after standard treatment or cannot receive it. The drugs block adenosine receptors, which tumors use to quiet th…
Phase 1/2 • Sponsor: Portage Biotech • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Shorter hormone therapy meets precision radiation in High-Risk prostate cancer
Disease control Recruiting nowResearchers are testing whether men with high-risk localized prostate cancer can safely receive a shorter course of hormone therapy alongside focused, dose-escalated radiation to the prostate. The trial enrolls 30 men and uses an AI-based classifier to help tailor treatment. All …
Phase 2 • Sponsor: German Oncology Center, Cyprus • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug EVOLVE104 takes on tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…
Phase 1 • Sponsor: EvolveImmune United, Inc • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New gene therapy injection aims to boost prostate cancer radiation results
Disease control Recruiting nowThis study tests a gene therapy called aglatimagene besadenovec, given with valacyclovir, in 45 men with intermediate-risk prostate cancer who will also receive radiation. The main goal is to see how the therapy spreads in the body and to measure immune responses and tumor marker…
Phase 2 • Sponsor: Candel Therapeutics, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for men with spread prostate cancer: targeted radiation may boost standard care
Disease control Recruiting nowThis study is for men with prostate cancer that has spread to a few other parts of the body at diagnosis. It tests whether adding radiation therapy directly to those cancer spots (called metastasis-directed radiotherapy) can help keep the cancer under control longer than the usua…
Phase 2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for brain infection: experimental combo tackles tuberculous meningitis
Disease control Recruiting nowThis study tests a new combination of medicines (BPaLMZ) against the standard treatment for tuberculous meningitis, a serious brain infection. About 240 adults, including those living with HIV, will take part. The goal is to see if the new combo helps more people survive and reco…
Phase 2 • Sponsor: David Boulware • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: experimental drug ubamatamab enters phase 2 trials
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called ubamatamab, alone or combined with other cancer drugs, in 220 people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The study aims to see how…
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Less invasive surgery may improve recovery for ovarian cancer patients
Disease control Recruiting nowThis study compares two surgical approaches for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have received chemotherapy before surgery. One group will have minimally invasive surgery (small incisions), and the other will have standard open surger…
Phase 3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a month of pills boost radiation for prostate cancer?
Disease control Recruiting nowThis study tests whether adding a short, 30-day course of the oral hormone drug Relugolix to standard targeted radiation (SBRT) works better than radiation alone for men with intermediate-risk prostate cancer. About 60 men will be randomly assigned to one of the two treatments. T…
Phase 2 • Sponsor: Yale University • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…
Phase 1/2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for rare cancers: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
A balloon that coats heart arteries in drug, no stent left behind
Disease control Recruiting nowResearchers are testing whether a balloon catheter coated with the drug sirolimus can safely open narrowed coronary arteries in adults with heart disease. The balloon inflates to press the drug into the artery wall, aiming to keep the vessel open without leaving a permanent stent…
Sponsor: Tonic Medical, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New smart drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…
Phase 1/2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for recurrent ovarian cancer: targeted drug combo enters human trials
Disease control Recruiting nowThis study tests a new drug called SHR-A1811 combined with standard chemotherapy (carboplatin and bevacizumab) in 150 women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to find the safest dose and see if the combination shrinks tumors …
Phase 1/2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Nerve wrap aims to prevent erectile dysfunction after prostate removal
Disease control Recruiting nowThis trial tests whether wrapping the nerves around the prostate with a special tissue allograft during surgery can reduce erectile dysfunction and incontinence. 25 men with localized prostate cancer will receive the wrap during nerve-sparing prostate removal. The study focuses o…
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New prostate cancer drug enters first human trials
Disease control Recruiting nowThis early-stage trial tests a new oral drug called INR731, alone or with standard hormone therapy drugs, in 208 men with metastatic prostate cancer that no longer responds to hormone treatment. The main goals are to check safety, find the right dose, and see if the drug shows an…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for men with Hard-to-Treat prostate cancer: drug combo trial launches
Disease control Recruiting nowThis phase 3 trial is testing whether adding the experimental drug xaluritamig to standard abiraterone helps men with metastatic castration-resistant prostate cancer live longer. About 750 participants who have not yet had chemotherapy will be randomly assigned to receive either …
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Antibody-Drug combo takes aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests a new drug called raludotatug deruxtecan (R-DXd) in people whose high-grade serous ovarian, peritoneal, or fallopian tube cancer has returned after platinum chemotherapy. R-DXd is an antibody-drug conjugate that seeks out cancer cells and delivers a toxic payload…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New antibody drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Immune-Boosting drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug, REGN15505, alone or with other drugs, in adults with advanced prostate or kidney cancer that has spread. The goal is to help the immune system attack cancer cells. About 265 participants will be enrolled to check safety, side effects, and …
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug MAR002 aims to tame acromegaly in early trial
Disease control Recruiting nowThis Phase 2 trial tests a new drug called MAR002 in 72 adults with acromegaly, a condition caused by a pituitary tumor that leads to too much growth hormone. Participants will receive either MAR002 or a placebo as injections under the skin. The study will check if the drug is sa…
Phase 2 • Sponsor: Marea Therapeutics • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New immunotherapy combo shows promise for tough cancers
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called volrustomig, either alone or with chemotherapy, in people with advanced cervical, head and neck, esophageal, or mesothelioma cancers. The study aims to see if the drug can shrink tumors and how safe it is. About 257 partic…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New antibody combo aims to fight back against recurrent ovarian cancer
Disease control Recruiting nowThis study is testing a new drug called ubamatamab, given alone or with another drug called cemiplimab, in people with ovarian cancer or other cancers that have come back after treatment. The main goals are to check safety, find the right dose, and see if the drugs can shrink tum…
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New 'seek and destroy' therapy for metastatic cancer enters human testing
Disease control Recruiting nowThis early-stage study tests a two-part system to find and treat metastatic cancer. First, a radioactive tracer is used to spot tumors on a PET scan. Then, a similar radioactive drug is given to deliver radiation directly to the cancer cells. The goal is to see if this approach i…
Phase 1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Could a Weight-Loss drug slow endometrial cancer growth?
Disease control Recruiting nowThis study tests whether tirzepatide, a drug used for weight loss and diabetes, can slow tumor growth in people with obesity-driven endometrial cancer. About 20 participants will take the drug before their scheduled hysterectomy. Researchers will compare cancer cell activity in t…
Early phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Could a Two-Drug HIV pill work for TB patients?
Disease control Recruiting nowThis study tests whether a two-drug HIV regimen (dolutegravir plus lamivudine) works as well as the standard three-drug regimen in people who also have tuberculosis and are on TB treatment. About 150 participants who have never taken HIV medication will be randomly assigned to on…
Phase 3 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo aims to outsmart resistant ovarian cancer
Disease control Recruiting nowThis early-phase trial is testing whether combining two targeted drugs—abemaciclib and olaparib—can help women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The study will enroll 42 participants to find the safest dose and check for side effects.…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Could a 'Microbiome Transplant' stop recurring vaginal infections?
Disease control Recruiting nowThis study tests whether transplanting vaginal fluid from healthy donors can restore a healthy bacterial balance in women with recurrent bacterial vaginosis (BV). Participants receive either the transplant or a placebo after antibiotic treatment. The goal is to see if the transpl…
Phase 1/2 • Sponsor: Douglas Kwon • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo targets tough ovarian cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called DT2216 combined with the chemotherapy paclitaxel in people whose ovarian cancer has returned and is resistant to platinum-based treatments. The main goal is to find the highest safe dose of DT2216 when given with paclitaxel. About 30…
Phase 1 • Sponsor: Elizabeth Stover, MD, PhD • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug BL-M07D1 targets multiple HER2 cancers in early trial
Disease control Recruiting nowThis Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Exercise program aims to fight frailty in prostate cancer patients
Disease control Recruiting nowThis study tests whether a 16-week supervised exercise program (circuit training with resistance, functional, and aerobic exercises) can improve frailty and muscle loss in 80 men with metastatic prostate cancer who are on hormone therapy. Participants must be pre-frail or frail. …
Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug FORX-428 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …
Phase 1 • Sponsor: FoRx Therapeutics AG • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for tough prostate cancer: first human trial of VIR-5500 begins
Disease control Recruiting nowThis early-stage study tests a new drug called VIR-5500 in people with advanced prostate cancer that has stopped responding to hormone treatment. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or lower PSA levels. …
Phase 1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a Hormone-Blocking drug boost chemotherapy against prostate cancer?
Disease control Recruiting nowResearchers are testing whether adding darolutamide to docetaxel or cabazitaxel chemotherapy helps men with metastatic castration-resistant prostate cancer whose disease has worsened on a hormone-blocking drug. The trial enrolls about 245 men and randomly assigns them to receive …
Phase 2 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for hard-to-treat prostate cancer: immunotherapy plus targeted radiation
Disease control Recruiting nowThis study tests a combination of two drugs—pembrolizumab (an immunotherapy) and 177Lu-PSMA-617 (a targeted radiation therapy)—in men with advanced prostate cancer that has stopped responding to hormone treatments. The goal is to see if this combo can slow or stop cancer growth. …
Phase 2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo aims to shrink advanced cervical tumors
Disease control Recruiting nowThis study tests whether combining two drugs, pembrolizumab and lenvatinib, can shrink tumors in people with advanced cervical cancer that has stopped responding to initial treatment. The trial enrolls 35 adults whose cancer has spread or cannot be removed by surgery. The goal is…
Phase 2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis early-phase trial is testing a new treatment called B7-H3 CAR T cells for adults with ovarian cancer that has come back and no longer responds to platinum chemotherapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize an…
Phase 1 • Sponsor: Stanford University • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Hormone blockers and letrozole tested to spare uterus in early endometrial cancer
Disease control Recruiting nowResearchers are testing a combination of a gonadotropin-releasing hormone agonist injection and the drug letrozole in obese women with early-stage endometrial cancer that has not responded to progestin. The goal is to see if this hormone-blocking approach can shrink tumors and al…
Phase 2/3 • Sponsor: Xiaojun Chen • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug CR-001 enters human trials
Disease control Recruiting nowThis study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.
Phase 1/2 • Sponsor: Crescent Biopharma, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Quick HIV meds may slash stigma for drug users
Disease control Recruiting nowThis study tests whether starting antiretroviral therapy within 7 days of an HIV diagnosis can reduce stigma and improve health outcomes for people who inject drugs. Researchers will develop a rapid-start strategy and pilot it with 135 participants at HIV clinics. The goal is to …
Sponsor: Yale University • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Hormone shots plus vaccine aims to supercharge immune attack on prostate cancer
Disease control Recruiting nowThis phase II trial tests whether adding bipolar androgen therapy (cycles of testosterone) to the standard Sipuleucel-T vaccine can boost the immune response in men with metastatic castration-resistant prostate cancer. About 26 participants will receive both treatments, and resea…
Phase 2 • Sponsor: Yale University • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can local clinics keep more people with HIV in care?
Disease control Recruiting nowResearchers in Peru are studying whether moving HIV care from specialized hospitals to primary health clinics helps more people stay in treatment and keep the virus suppressed. The trial combines two training programs, NIATx and Project ECHO, to give primary care staff the skills…
Sponsor: Yale University • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Hormone combo tested as Fertility-Sparing option for early uterine cancer
Disease control Recruiting nowResearchers test whether a combination of GnRHa and letrozole can shrink early endometrial cancer or atypical hyperplasia in non-obese patients who have not responded to progestin therapy. The trial compares this regimen with Diane-35 plus metformin. About 80 participants receive…
Phase 2/3 • Sponsor: Xiaojun Chen • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could 5 radiation doses replace 45 for prostate cancer?
Disease control Recruiting nowThis study compares a new, shorter radiation treatment (5 sessions over 2 weeks) to the standard longer course (20-45 sessions over 4-9 weeks) for men with high-risk prostate cancer. The goal is to see if the shorter approach works just as well at preventing the cancer from sprea…
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could a gel stop genital warts from coming back?
Disease control Recruiting nowThis phase 2 trial tests whether applying a special gel (Geniwa gel) after laser removal can better treat recurrent genital warts and prevent them from returning. Adults who have had at least three laser treatments and still experience recurrences are eligible. Participants recei…
Phase 2 • Sponsor: KTH Biopharma • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could oral antibiotics replace hospital stays for Syphilis-Exposed newborns?
Disease control Recruiting nowThis study tests whether oral antibiotics (linezolid or amoxicillin) can effectively treat newborns at risk of congenital syphilis, compared to a standard penicillin shot. The goal is to find a safe, outpatient-friendly option that avoids long hospital stays. The trial involves 9…
Phase 2 • Sponsor: London School of Hygiene and Tropical Medicine • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
A Hormone-Free IVF path? Lab-Matured eggs put to the test
Disease control Recruiting nowThis pilot study tests whether eggs can be collected from small ovarian follicles without the usual hormone injections. Women aged 18 to 35 with infertility will undergo up to three unstimulated egg retrievals. The eggs are matured in the lab using a device called CAPA-IVM, then …
Sponsor: Kevin Doody • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for rare, deadly gynecologic cancers: drug combo trial launches
Disease control Recruiting nowThis clinical trial is testing whether a combination of two drugs—dostarlimab (an immunotherapy) and niraparib (a PARP inhibitor)—works better than standard chemotherapy for women with a rare and aggressive type of uterine or ovarian cancer called carcinosarcoma. The study will e…
Phase 2/3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can early HIV treatment free infants from lifelong meds?
Disease control Recruiting nowThis study tests whether giving very early and intensive antiretroviral therapy, plus an antibody, can help infants with HIV achieve remission—meaning the virus stays undetectable even after stopping treatment. Researchers will enroll about 1,120 infants and follow them for safet…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Personalized mRNA vaccine aims to train immune system against ovarian cancer
Disease control Recruiting nowThis trial tests a personalized mRNA vaccine called NeoOVIV in people with stage II or III ovarian cancer who have had surgery. The vaccine is designed to teach the immune system to recognize and attack cancer cells. Participants receive the vaccine alongside standard chemotherap…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for tough prostate cancer? drug trial targets resistant tumors
Disease control Recruiting nowThis phase 2 trial tests an oral drug called pacritinib in 32 men with metastatic castrate-resistant prostate cancer that has worsened after standard treatments. The drug is taken twice daily, and the main goal is to see if it can delay cancer growth for at least six months. Part…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo aims to extend remission in ovarian cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding the experimental drug Rina-S to standard care (bevacizumab or monitoring) can help keep platinum-sensitive ovarian cancer from returning after chemotherapy. About 528 participants will receive either Rina-S alone, Rina-S plus bevacizumab, b…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New smart drug targets tough cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo aims to shrink ovarian tumors before surgery
Disease control Recruiting nowThis study tests whether giving the targeted drug mirvetuximab soravtansine together with standard chemotherapy (carboplatin) before surgery can shrink advanced ovarian, fallopian tube, or peritoneal cancers that have a specific protein (FRα). About 140 adults with stage III or I…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for recurrent endometrial cancer: Rina-S faces off against standard chemo
Disease control Recruiting nowThis study compares a new drug called Rina-S to standard chemotherapy (paclitaxel or doxorubicin) in people with endometrial cancer that has returned or worsened after platinum-based chemo and immunotherapy. About 660 participants will be randomly assigned to receive either Rina-…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New radiation technique aims to spare the urethra in prostate cancer treatment
Disease control Recruiting nowThis trial is testing a daily adaptive radiation therapy for low to intermediate risk prostate cancer that spares the urethra. The goal is to reduce urinary side effects compared to standard radiation. About 132 participants will receive this tailored radiation, and their urinary…
Sponsor: Varian, a Siemens Healthineers Company • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New program aims to restore sexual function after prostate cancer surgery
Disease control Recruiting nowThis trial tests whether a combination of a daily erectile medication, pelvic floor exercises, aerobic exercise, dietary advice, and mental health support can improve erectile function and urinary control in men after robot-assisted prostate removal for prostate cancer. Sixty-fou…
Phase 2 • Sponsor: Surgical Outcomes Research Centre (SOuRCe) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New cancer drug AGX101 enters human trials for advanced tumors
Disease control Recruiting nowThis early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…
Phase 1 • Sponsor: Angiex, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New radioactive drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests an experimental drug called AZD8359 for men with metastatic prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to guide the body's immune cells to attack cancer cells. The trial will first find the safest dose…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
HIV-Positive livers for HIV-Positive patients: a new hope?
Disease control Recruiting nowThis study looks at whether people with HIV who need a liver transplant can safely receive a liver from a donor who also had HIV. Researchers will compare infections and cancer rates between those who get an HIV-positive donor liver and those who get an HIV-negative donor liver. …
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: Rina-S trial launches
Disease control Recruiting nowThis phase 3 trial compares a new drug called Rina-S to standard chemotherapy in 82 people with platinum-resistant ovarian cancer. Participants are randomly assigned to receive either Rina-S or one of four approved chemotherapies. The goal is to see if Rina-S can delay cancer gro…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Could a shot replace daily HIV pills? new trial tests injectable combo
Disease control Recruiting nowThis study tests whether an injectable combination of two experimental drugs, GS-3242 and lenacapavir, can control HIV-1 as well as the daily pill Biktarvy. About 700 people with HIV who have never taken antiviral treatment will receive either the injectable regimen or the standa…
Phase 2/3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Could a weekly pill replace daily HIV treatment? new study aims to find out.
Disease control Recruiting nowThis study tests whether a once-weekly combination of two experimental drugs (islatravir and ulonivirine) works as well as the standard daily three-drug pill Biktarvy for people newly diagnosed with HIV-1. About 570 adults who have never taken HIV medication will be randomly assi…
Phase 2/3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a custom mRNA vaccine keep ovarian cancer from coming back?
Disease control Recruiting nowThis early-phase trial is testing whether a personalized mRNA vaccine called NeoOVSV, given alongside standard chemotherapy and an immunotherapy drug, can safely help prevent ovarian cancer from returning after surgery. The vaccine is designed to train the immune system to recogn…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Kids with HIV get continued access to lifesaving meds in new study
Disease control Recruiting nowThis study offers continued access to HIV medications for children and adolescents who completed a previous Gilead HIV treatment study. About 350 participants will receive their study drug or switch to a standard HIV medication, and researchers will monitor for side effects. The …
Phase 4 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Could a lighter touch in IVF yield healthier embryos for women over 35?
Disease control Recruiting nowThis trial tests whether a lower daily dose of the fertility drug Rekovelle can produce as many healthy embryos as a higher dose in women of advanced age undergoing IVF with genetic screening. Participants receive either 15 or 20 micrograms per day during ovarian stimulation. Res…
Phase 4 • Sponsor: Fundación Santiago Dexeus Font • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug combo aims to outsmart advanced prostate cancer
Disease control Recruiting nowThis study is for men with a type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. It tests whether adding a new drug called SX-682 to the existing drug apalutamide is safe and can shrink tumors or slow the cancer. About 78 men will …
Phase 1/2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New radiation strategy aims to deepen prostate cancer remission
Disease control Recruiting nowThis study tests whether adding targeted radiation to spots where prostate cancer has spread can help men whose cancer is already responding to hormone therapy. About 80 men with metastatic prostate cancer will be randomly assigned to get either standard care or standard care plu…
Phase 2 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New antibody drug aims to turn immune cells against cancer
Disease control Recruiting nowThis early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…
Phase 1 • Sponsor: NextPoint Therapeutics, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-phase trial tests a combination of two drugs—DS-8201a and olaparib—in people with advanced HER2-expressing cancers that have spread or cannot be removed. DS-8201a delivers chemotherapy directly to HER2-positive tumor cells, while olaparib blocks DNA repair in cancer ce…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New antibody drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called ONC-783 in 20 people with advanced solid tumors, including colorectal, ovarian, pancreatic, or breast cancer. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goal is to find a safe d…
Phase 1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug combo aims to boost IVF success for women with hormone deficiency
Disease control Recruiting nowThis Phase 3 trial tests a new combination of two hormones (follitropin alfa and lutropin alfa) against a standard treatment (hMG) for Japanese women with LH and FSH deficiency who are undergoing IVF. The goal is to see which treatment helps produce more eggs for retrieval. About…
Phase 3 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for advanced prostate cancer: experimental drug enters human trials
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called RO7656594 in people with advanced or metastatic prostate cancer that has progressed after standard treatments. The study aims to find safe doses and check for any signs that the drug can shrink tumors or lower PSA…
Phase 1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new drug tame metastatic prostate cancer? a phase 1 trial aims to find out
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called SHR-6914 in men with prostate cancer that has spread to other parts of the body. The main goal is to see if the drug is safe and tolerable, and to find the right dose for future studies. Participants must have a confir…
Phase 1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for ovarian cancer: phase 3 trial tests targeted drug against Tough-to-Treat tumors
Disease control Recruiting nowThis large Phase 3 study tests a new medicine called Sofetabart Mipitecan for people with ovarian, fallopian tube, or peritoneal cancer. It includes two groups: those whose cancer stopped responding to platinum chemotherapy within six months (platinum-resistant), and those whose …
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for advanced cervical cancer: adding immunotherapy before standard care
Disease control Recruiting nowThis phase III trial tests whether giving an extra round of chemotherapy and immunotherapy (pembrolizumab) before the usual chemoradiation can help people with high-risk, locally advanced cervical cancer live longer without the cancer growing. About 336 participants will be rando…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Heart hope: HIV-positive women may get better blood flow with common diabetes pills
Disease control Recruiting nowThis study looks at whether SGLT2 inhibitors, a class of diabetes and kidney drugs, can improve blood flow through the heart's small arteries in women with HIV who also have diabetes or chronic kidney disease. Eighty women aged 45-75 will be randomly assigned to health education …
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called AZD4956, alone or with other cancer drugs, in people with advanced or spreading solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. …
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a daily pill replace growth hormone shots for kids?
Disease control Recruiting nowThis study tests an oral medication called LUM-201 for children with growth hormone deficiency who have never been treated before. The goal is to see if taking a pill every day for 12 months can improve growth rate compared to a placebo. The study involves 150 prepubertal childre…
Phase 3 • Sponsor: Lumos Pharma • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New radioactive drug targets FAP-Positive tumors in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Lab-Grown immune cells take on dangerous viruses in vulnerable patients
Disease control Recruiting nowThis study tests whether specially grown donor immune cells (called cytotoxic T lymphocytes) can safely and effectively control BK and JC virus infections in people with weakened immune systems, such as those with cancer, HIV, or organ transplants. About 100 participants will rec…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
A new test may spot which women need pain care before endometriosis surgery
Disease control Recruiting nowThis trial tests whether screening women with endometriosis for pain complications before surgery, and offering specialized pain care to those who need it, improves their quality of life a year after the operation. Researchers will compare women who receive this extra pain manage…
Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Diabetes drug shows promise for dangerous low sodium condition
Disease control Recruiting nowThis study tests whether the diabetes drug empagliflozin (Jardiance) can safely raise low sodium levels in people with certain conditions like SIADH, liver failure, or kidney failure. About 172 adults with chronic low sodium will receive either the drug or a placebo for up to 30 …
Phase 4 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Could extra antibiotics help prolong pregnancy after early water break?
Disease control Recruiting nowThis pilot study tests whether adding extra doses of the antibiotic azithromycin to standard care can improve outcomes for pregnant people whose water breaks very early (between 22 and 28 weeks). Thirty participants will be randomly assigned to receive either the standard antibio…
Phase 4 • Sponsor: Alexa Henderson • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Could a shot replace daily HIV pills? new trial tests Two-Injection combo
Disease control Recruiting nowThis Phase 2 trial tests whether switching to a combination of two injectable drugs, GS-3242 and lenacapavir, works as well as staying on the daily pill Biktarvy for people with HIV who already have the virus under control. About 175 participants will be randomly assigned to eith…
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Half the dose, same hope? trial tests cutting hormone therapy in prostate cancer
Disease control Recruiting nowThis phase 3 trial is testing whether giving men with metastatic prostate cancer half the standard dose of certain hormone therapies (called ARPIs) can be just as effective as the full dose, while causing less fatigue and fewer treatment stoppages. About 1,500 men with prostate c…
Phase 3 • Sponsor: University College, London • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for advanced prostate cancer: experimental drug GDC-1261 enters trials
Disease control Recruiting nowThis study tests a new drug called GDC-1261 in 260 people with advanced or metastatic prostate cancer that has worsened after prior treatment. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors or lower PSA levels. Participants must alread…
Phase 1/2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for tough cancers: experimental drug IMGS-001 enters human trials
Disease control Recruiting nowThis early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…
Phase 1 • Sponsor: ImmunoGenesis • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for tough endometrial cancer: Four-Drug combo trial launches
Disease control Recruiting nowThis Phase III trial tests whether adding the drug bevacizumab to a standard chemotherapy plus immunotherapy regimen can help people with a specific type of advanced or recurrent endometrial cancer (pMMR, TP53 mutated). About 255 participants will be randomly assigned to one of t…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a shot and a vaccine free people with HIV from daily pills? early trial aims to find out.
Disease control Recruiting nowThis early-stage study tests whether giving two powerful antibodies along with a therapeutic HIV vaccine can help people with HIV control the virus after they stop their daily antiretroviral therapy. The trial enrolls 48 adults in Thailand who started HIV treatment very soon afte…
Phase 1 • Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New cell therapy targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ZI-MA4-1, made from specially engineered immune cells, in people with advanced ovarian, lung, sarcoma, or head and neck cancers that have not responded to other therapies. The treatment aims to help the body's immune system atta…
Phase 1 • Sponsor: Zelluna Immunotherapy AS • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Radioactive 'Smart Bombs' target Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests two radioactive drugs, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, in people with advanced solid tumors that have a protein called GRPR on their surface. These cancers include certain breast, prostate, and colorectal cancers that have stopped responding …
Phase 1 • Sponsor: Alpha-9 Oncology USA Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new radioactive drug called 177Lu-FC516 in 13 men with advanced prostate cancer that has stopped responding to standard treatments. The drug is given every 6 weeks for up to 4 cycles. The main goals are to find the safest dose and check for side eff…
Early phase 1 • Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
MRI-Guided prostate cancer treatment cuts radiation to just 2 doses
Disease control Recruiting nowThis study tests a new way to give radiation for prostate cancer using only 2 treatments instead of the usual 39. Doctors will use MRI scans to see how the tumor responds after the first dose, then adjust the second dose to target the cancer more precisely. The goal is to see if …
Phase 2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat ovarian and endometrial cancers
Disease control Recruiting nowThis early-phase trial is testing the safety and best dose of two drugs, M1774 and ZEN-3694, given together to patients with recurrent ovarian or endometrial cancer. The drugs work by blocking enzymes that cancer cells need to grow. The study aims to find a dose that is safe and …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can frozen tissue preserve fertility for children with DSD?
Disease control Recruiting nowThis study tests whether gonadal tissue removed from children with disorders of sex development (DSD) can be frozen and stored to preserve fertility. The tissue is already being removed for medical reasons, such as preventing cancer. Researchers will check the tissue for viable g…
Sponsor: Erin Rowell • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New biologic drug JANX014 enters first human trial for tough prostate cancer
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug, JANX014, in 43 men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The main goal is to check safety and find the right dose, while also looking at how the drug moves through th…
Phase 1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug cocktail aims to slow prostate cancer spread
Disease control Recruiting nowThis study tests whether adding an experimental drug called PDS01ADC to standard chemotherapy (docetaxel) can help men with prostate cancer that has spread to other parts of the body. About 86 men with either castration-sensitive or castration-resistant metastatic prostate cancer…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for recurrent prostate cancer: drug combo aims to control PSA without hormone therapy
Disease control Recruiting nowThis study tests whether adding an injected drug (PDS01ADC) to a daily pill (enzalutamide) can better control PSA levels in men whose prostate cancer has returned after initial treatment. About 65 participants will receive either enzalutamide alone or both drugs for 3 months, wit…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a shorter hormone course plus precision radiation curb prostate cancer spread?
Disease control Recruiting nowThis phase II trial tests whether 6 months of androgen deprivation therapy (ADT) combined with dose-escalated radiotherapy can reduce the risk of distant metastasis in men with high-risk prostate cancer who have lower ARTERA scores. Participants receive standard ADT (degarelix, l…
Phase 2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a vaginal bacteria capsule boost IVF success?
Disease control Recruiting nowThis study tests a new treatment called FB301, a capsule containing beneficial bacteria, for women with an imbalance of vaginal bacteria who have had a failed frozen embryo transfer (IVF). Thirty women aged 18-40 will receive FB301 or a placebo during a mock IVF cycle, with some …
Phase 2 • Sponsor: Freya Biosciences ApS • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New pill targets HER2 cancers in promising trial
Disease control Recruiting nowThis Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…
Phase 2 • Sponsor: Bayer • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug IDP-001 takes on advanced cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…
Phase 1/2 • Sponsor: InduPro, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug cocktail aims to outsmart aggressive uterine cancer
Disease control Recruiting nowThis phase 3 trial is testing whether a targeted drug (trastuzumab deruxtecan) combined with immunotherapy (rilvegostomig or pembrolizumab) works better than standard chemotherapy plus pembrolizumab for people with advanced or recurrent endometrial cancer that has a specific prot…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Same-Day HIV pill restart help patients get back on track?
Disease control Recruiting nowThis study looks at whether people with HIV who have stopped their medication for at least 12 weeks can safely restart treatment with a single daily pill (B/F/TAF) on the same day they return to care. About 200 adults will take part to see if this quick restart helps lower the vi…
Phase 4 • Sponsor: CAN Community Health • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for tough prostate cancer: experimental drug takes on standard treatments
Disease control Recruiting nowThis large Phase 3 trial is testing a new oral drug called opevesostat (MK-5684) against two standard drugs (abiraterone or enzalutamide) in men with metastatic castration-resistant prostate cancer that has worsened after prior hormone therapy and chemotherapy. The study aims to …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new drug tackle Hard-to-Treat gynecologic cancers?
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called ARR-002 in adults with advanced or metastatic ovarian or endometrial cancer, including cases that have stopped responding to platinum-based chemotherapy. The main goals are to assess the drug's safety, tolerability,…
Phase 1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New shot could simplify prostate cancer treatment
Disease control Recruiting nowThis phase 2 trial tests ASP5541, a new injectable form of the hormone therapy abiraterone, in men with advanced prostate cancer that has spread. The study compares ASP5541 (given every 12 weeks) to daily abiraterone pills, both with or without steroids. About 218 men with metast…
Phase 2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New antibody takes aim at Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called CTIM-76 in people with advanced ovarian, testicular, or endometrial cancers that have not responded to standard treatments. CTIM-76 is a bispecific antibody designed to attach to a protein called Claudin-6 on cancer cells and he…
Phase 1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Two-Drug attack stall resistant prostate cancer?
Disease control Recruiting nowThis phase 3 trial is testing whether adding an experimental drug called rinzimetostat to the standard drug darolutamide can slow the progression of metastatic castration-resistant prostate cancer better than current treatments. The study enrolls men whose cancer has worsened aft…
Phase 3 • Sponsor: ORIC Pharmaceuticals • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for tough prostate cancer: drug combo trial launches
Disease control Recruiting nowThis study tests whether a new combination of two drugs, inavolisib and enzalutamide, works better than standard treatments for men with metastatic castration-resistant prostate cancer that has progressed after one prior therapy. About 100 men will be randomly assigned to receive…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug combo aims to keep ovarian cancer at bay longer
Disease control Recruiting nowThis phase 3 trial tests whether a new drug, sacituzumab tirumotecan, given with or without bevacizumab, can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 participants who have already completed two rounds of ch…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Weekly shot could replace daily growth hormone for kids
Disease control Recruiting nowThis phase 3 trial compares a once-weekly growth hormone injection (lonapegsomatropin) to a daily one (somatropin) in 186 prepubertal children with growth failure due to Turner syndrome, SHOX deficiency, being small for gestational age, or idiopathic short stature. The goal is to…
Phase 3 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New antibody therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests an experimental drug called AZD6621 for men with metastatic prostate cancer that has spread. The drug is designed to help the body's immune cells attack cancer cells. The trial has two parts: first, finding the safest dose, then testing that dose in more people t…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Triple therapy may extend lives in advanced prostate cancer
Disease control Recruiting nowThis study tests whether adding the chemotherapy drug docetaxel to the usual hormone therapy and apalutamide helps men with prostate cancer that has spread to other parts of the body live longer. About 1,260 men will be randomly assigned to receive either the three-drug combinati…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New pill may help adults with rare adrenal disorder cut back on steroids
Disease control Recruiting nowThis study tests a new drug, atumelnant, in 150 adults with classic congenital adrenal hyperplasia (CAH). The goal is to see if it can safely control hormone levels and allow patients to take lower doses of their usual steroid medications. Participants will receive either atumeln…
Phase 3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New combo therapy for endometrial cancer tested in Real-World setting
Disease control Recruiting nowThis study is tracking the safety and effectiveness of durvalumab (with or without olaparib) in about 50 Korean patients with endometrial cancer who are already prescribed these drugs. Researchers will follow participants for up to 12 months to see how well the treatment works in…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
BioNTech launches trial of BNT326 for advanced cancers
Disease control Recruiting nowThis study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Gene-Guided therapy could revolutionize prostate cancer care
Disease control Recruiting nowThis study tests whether analyzing a patient's tumor DNA and RNA can help doctors select the most effective treatment for advanced prostate cancer that no longer responds to hormone therapy. About 474 participants will receive one of several drugs based on their genetic profile. …
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Good bacteria vs. bad: new trial aims to stop BV from coming back
Disease control Recruiting nowThis study tests whether a probiotic supplement containing Lactobacillus crispatus can reduce the number of times bacterial vaginosis (BV) comes back in women who have had it repeatedly. About 156 women aged 18-45 will take either the probiotic or a placebo daily for 12 weeks aft…
Sponsor: Liaquat University of Medical & Health Sciences • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug DSB2455 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…
Phase 1 • Sponsor: Duke Street Bio Ltd • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could a longer break between prostate cancer treatments boost quality of life?
Disease control Recruiting nowThis phase 3 trial for men with advanced, hormone-resistant prostate cancer tests whether giving the drug lutetium-177 PSMA less often (only when the disease shows signs of activity) can improve quality of life without shortening survival. About 1,500 participants will be randoml…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New pill could help kids with rare hormone disorder cut back on steroids
Disease control Recruiting nowThis study tests a daily oral medication called atumelnant in children aged 1 to 18 with classic congenital adrenal hyperplasia, a genetic condition that disrupts hormone production. The goal is to see if the drug can safely normalize hormone levels and allow patients to lower th…
Phase 2/3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug duo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…
Phase 1/2 • Sponsor: Pyxis Oncology, Inc • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New Egg-Maturing solution could boost IVF success
Disease control Recruiting nowThis study tests whether Fertilo, a new solution for maturing eggs outside the body, works better than the current standard (MediCult IVM) for women aged 18-35 undergoing IVF. About 500 participants will have their eggs treated with either Fertilo or MediCult, and researchers wil…
Phase 3 • Sponsor: Gameto, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new formulation of an endometriosis drug match the standard?
Disease control Recruiting nowThis trial compares HHK001, an investigational version of leuprorelin acetate, to Enantone, an approved treatment for endometriosis. Both contain the same active ingredient, but HHK001 uses an updated formulation. The study will enroll 30 women aged 18-45 with endometriosis, who …
Phase 1 • Sponsor: Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New CAR T-Cell therapy takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental therapy called FT836, a ready-made CAR T-cell treatment, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to prior treatments. The main goals are…
Phase 1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New antibody cocktail aims to block HIV without daily pills
Disease control Recruiting nowThis early-stage trial is testing whether lab-made antibodies that target HIV are safe and how long they stay in the body. About 83 healthy adults without HIV will receive the antibodies by vein or under the skin, alone or in combination. The goal is to find the right dose and ch…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New antibody BNT351 enters first human trial for HIV
Disease control Recruiting nowThis early-stage study tests a new antibody called BNT351 in 67 adults, both with and without HIV. The goal is to check safety, how long the antibody stays in the blood, and whether it can lower HIV levels in people with the virus. It is a first step toward possibly controlling H…
Phase 1 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Radioactive therapy aims to stall prostate cancer spread without hormone drugs
Disease control Recruiting nowThis phase 3 trial tests a radioactive drug called lutetium-177 vipivotide tetraxetan in 450 men whose prostate cancer has returned and spread to a few spots after initial treatment. The drug targets a protein on cancer cells and delivers radiation directly to them. The goal is t…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Double radiation attack aims to stop prostate cancer bone breaks
Disease control Recruiting nowThis phase 2 trial tests whether adding precise external beam radiation to standard radioligand therapy can better control metastatic prostate cancer that no longer responds to hormone therapy. About 120 participants will receive either standard treatment alone or combined with t…
Phase 2 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug cocktail aims to tackle Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called CBP-1019 combined with standard chemotherapy (FOLFOX) and possibly other drugs for people with advanced solid tumors that have not responded to prior treatments. The goal is to find safe and effective doses. About 128 participants wi…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a smart radiation drug hunt down prostate cancer cells?
Disease control Recruiting nowThis early-phase trial tests an investigational drug called SRT-017 in men with a type of advanced prostate cancer that has stopped responding to hormone therapy. The drug is designed to seek out and deliver radiation directly to cancer cells that carry a marker called PSMA. Rese…
Early phase 1 • Sponsor: Affiliated Hospital of Jiangnan University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a daily pill rescue erectile function when On-Demand treatments fail?
Disease control Recruiting nowThis trial compares two approaches for men with erectile dysfunction that doesn't respond well to on-demand PDE5 inhibitor pills: taking a low-dose tadalafil pill every day on its own, or taking it alongside the usual on-demand medication. Over 12 weeks, researchers will measure …
Phase 4 • Sponsor: Al-Azhar University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a targeted drug boost standard ovarian cancer therapy?
Disease control Recruiting nowThis trial is testing whether an experimental drug called TUB-040, when added to standard chemotherapy and a targeted therapy, is safe and tolerable for women with a specific type of advanced ovarian cancer. The study involves about 72 participants whose cancer has returned but s…
Phase 1/2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for ovarian cancer: Rina-S faces off against chemo in major trial
Disease control Recruiting nowThis large Phase 3 trial will test a new drug called Rina-S, alone or with bevacizumab, against standard platinum-based chemotherapy for women with ovarian cancer that has returned after initial treatment. About 688 participants will be randomly assigned to receive either the new…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new drug, GS-0415, help keep HIV in check? a First-in-Human trial aims to find out
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called GS-0415 in people with HIV who already have the virus well-controlled by standard antiretroviral therapy. The study will give single and multiple doses of GS-0415 to evaluate its safety, tolerability, and how the body …
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug cocktail aims to shrink recurrent ovarian tumors
Disease control Recruiting nowThis phase II trial tests an experimental drug called SYS6041, alone or combined with chemotherapy and other agents, in women whose ovarian cancer has returned. The study evaluates safety, the best dose, and how well the treatments shrink tumors. Participants must have a specific…
Phase 2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Tiny radioactive seeds may offer new hope for women with recurrent pelvic cancer
Disease control Recruiting nowThis study tests a radiation treatment called Cesium-131 brachytherapy for women whose cervical or endometrial cancer has returned in the vagina after prior pelvic radiation. Tiny radioactive seeds are placed directly into the tumor to kill cancer cells while sparing healthy orga…
Sponsor: Denise Fabian • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can one surgery treat endometrial cancer and obesity together?
Disease control Recruiting nowThis trial tests whether obese patients with endometrial cancer or a precancerous condition can safely undergo a hysterectomy and weight loss surgery at the same time. Researchers want to see if a fast-track referral process can get patients to surgery within 8 to 12 weeks of dia…
Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug cocktail aims to shrink tough prostate tumors before surgery
Disease control Recruiting nowThis study tests whether adding a drug called relacorilant to standard hormone therapy and enzalutamide can better shrink high-risk prostate cancer before surgery. About 90 people whose cancer has not responded to standard treatments will take the study drugs for 24 weeks, then h…
Phase 2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for hard-to-treat prostate cancer: targeted drug enters phase 2 trial
Disease control Recruiting nowThis study tests a drug called tarlatamab in people with a specific type of advanced prostate cancer (DLL3-positive) that has spread and either came back or didn't respond to prior treatments. About 32 participants will receive the drug to see if it can shrink tumors or slow the …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can AI learn to spot endometriosis and fibroids on ultrasound?
Diagnosis Recruiting nowResearchers at Semmelweis University are building and testing artificial intelligence algorithms that read standardized transvaginal ultrasound images. The study includes women aged 18 to 45 who have suspected endometriosis or adenomyosis, a confirmed uterine mass scheduled for s…
Sponsor: Semmelweis University • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
New imaging agent could reveal prostate cancer treatment success in real time
Diagnosis Recruiting nowThis phase 2 trial is testing whether a special PET scan tracer called 18F-DCFPyL can accurately show how prostate cancer responds to standard radiation therapy. About 130 adults with newly diagnosed, localized prostate cancer will receive the tracer and undergo PET/CT scans at s…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Light-Based imaging aims to spot prostate cancer left behind after surgery
Diagnosis Recruiting nowAfter surgery to remove prostate cancer, cancer cells sometimes remain at the edge of the removed tissue, which can lead to the cancer returning. Researchers are testing a light-based imaging method called hyperspectral imaging to examine the removed prostate and identify cancer …
Sponsor: Massimo Valerio • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can a new vaginal scanner map tumors and cut MRI reliance?
Diagnosis Recruiting nowResearchers at University Health Network in Toronto are testing a device called Vagina-View to see if it can clearly show vaginal tumor tissue and help position a brachytherapy applicator during treatment for vaginal cancer. Ten participants with gynecological cancer who are sche…
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Quick syphilis test at family planning visits studied in Hawai'i
Diagnosis Recruiting nowThis study looks at whether offering a rapid syphilis test during family planning visits (for birth control or abortion) is practical and acceptable to patients. About 70 participants will get a fingerstick test with results in 10-15 minutes, instead of waiting days. The goal is …
Sponsor: Queen's Medical Center • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Cervical smear DNA may reveal ovarian cancer years before symptoms
Diagnosis Recruiting nowHigh-grade serous ovarian cancer is often found too late, and no screening test exists. Researchers are studying whether DNA taken from routine cervical smears can show signs of this cancer early. They use a method called shallow-coverage whole genome sequencing to look for genom…
Sponsor: Institut Claudius Regaud • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
New imaging agent may reveal hidden prostate cancer recurrence
Diagnosis Recruiting nowThis study is testing whether a radioactive tracer called 18F-DCFPyL, used during a PET/CT scan, can better detect where prostate cancer has returned in men whose PSA levels are rising after initial treatment. About 350 men will be followed for up to 5 years with regular scans an…
Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Could new syphilis tests speed up diagnosis?
Diagnosis Recruiting nowThis study is testing two new blood test kits designed to diagnose syphilis. Researchers will collect blood samples from 1000 people, including those with symptoms, those at high risk, and healthy controls. The goal is to see how accurate these new kits are compared to standard l…
Sponsor: American Laboratory Products Company • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
New scan could spot returning prostate cancer earlier
Diagnosis Recruiting nowThis study tests a new PET/CT imaging agent called 68Ga-NYM032 in 232 men with suspected prostate cancer recurrence after initial treatment. Participants have rising PSA levels, and the scan aims to accurately locate any remaining cancer. The goal is to see how well the scan dete…
Phase 3 • Sponsor: Norroy Bioscience Co., LTD • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
AI ultrasound could bring lifesaving pregnancy checks to remote villages
Diagnosis Recruiting nowThis study tests whether a smartphone-based AI ultrasound, operated by health workers with minimal training, can accurately estimate gestational age, detect placenta position, and identify fetal presentation in pregnant women in rural Democratic Republic of the Congo. The goal is…
Sponsor: SOIK Corporation Sarl • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
New PET tracer aims to spot hidden cancer spread in the abdomen
Diagnosis Recruiting nowThis phase 2 study tests whether a radioactive tracer called [68Ga]BED003 can improve PET/CT scans for detecting cancer in the peritoneum (the lining of the abdomen). The trial includes adults with colorectal, ovarian, gastric, pancreatic, or a type of breast cancer. Researchers …
Phase 2 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
Blood test aims to catch Cancer's return earlier
Diagnosis Recruiting nowThe ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…
Sponsor: Guardant Health, Inc. • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Can a simple rinse reveal ovarian Cancer's earliest signs?
Diagnosis Recruiting nowThis study explores whether a uterine lavage—a procedure that rinses the fallopian tubes with saline to collect cells—can help detect early genetic changes linked to ovarian cancer in women with BRCA mutations. Participants are high-risk women planning risk-reduction surgery. Res…
Sponsor: University of Washington • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Sharper eye for prostate cancer: new imaging agent aims to spot hidden spread
Diagnosis Recruiting nowThis phase 3 trial tests a new radioactive imaging agent, 64Cu-SAR-bisPSMA, to see if it can better detect prostate cancer that has spread to nearby lymph nodes. About 383 men with high-risk prostate cancer will receive a single injection of the agent before their scheduled prost…
Phase 3 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
New Micro-Ultrasound could spot prostate cancer more clearly
Diagnosis Recruiting nowThis study tests whether a new type of ultrasound, called transperineal micro-ultrasound, can better detect prostate cancer during biopsy. Unlike standard ultrasound, this method uses higher frequency sound waves to create clearer images. Researchers will enroll 138 men scheduled…
Sponsor: Roswell Park Cancer Institute • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Can a personalised tool sharpen ovarian cancer risk prediction?
Diagnosis Recruiting nowResearchers are comparing two ways to assess ovarian cancer risk in people who are cancer-free but may be at higher risk because of family history or genetics. One approach follows standard national guidelines, using family history and sometimes genetic testing. The other uses th…
Sponsor: Instituto Portugues Oncologia de Lisboa Francisco Gentil • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
Can a phantom calibration system make prostate MRI reliable across all scanners?
Diagnosis Recruiting nowResearchers are testing a device called the CARE phantom system to see if it can make prostate MRI measurements more consistent across different scanners. The study includes men aged 18 and older who are undergoing prostate cancer investigation and have suspicious lesions on MRI.…
Sponsor: Gold Standard Phantoms • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
New tracer could sharpen prostate cancer detection
Diagnosis Recruiting nowThis early study tests a new radioactive tracer called 68Ga-FC516 in 10 healthy adults and people with prostate cancer. The goal is to see if it is safe and how well it finds tumors on PET/CT scans compared to existing tracers. The results will help improve prostate cancer diagno…
Early phase 1 • Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
Two proteins could give african clinics an early warning for dangerous pregnancy complication
Diagnosis Recruiting nowPreeclampsia is a serious high blood pressure condition that can develop during pregnancy and is a leading cause of death for mothers and babies in Africa. Doctors struggle to predict which women with high blood pressure will become severely ill because current tests are not accu…
Sponsor: Africa Clinical Research Network (ACRN) • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
New scan could clarify prostate cancer return when standard test fails
Diagnosis Recruiting nowThis study tests whether a special PET scan using fluciclovine can help doctors decide on treatment for men whose prostate cancer has returned after initial treatment, but whose standard PSMA PET scan was unclear or negative. About 142 men will receive the fluciclovine PET scan, …
Phase 4 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated Sep 10, 2026 00:00 UTC
-
A sharper eye for cancer: new PET tracer targets hidden tumors
Diagnosis Recruiting nowResearchers are testing whether a radioactive tracer called 68Ga/18F-PSMA/PSFA can improve PET/CT scans for finding tumors in people with PSMA-related cancers, including prostate and liver cancer. The study will enroll 500 adults with suspected, newly diagnosed, or previously tre…
Sponsor: Tianjin Medical University • Aim: Diagnosis
Last updated Sep 10, 2026 00:00 UTC
-
Can a wider biopsy needle sharpen prostate cancer diagnosis?
Diagnosis Recruiting nowProstate biopsies can misjudge cancer severity up to 40% of the time. This trial tests a new needle that collects more tissue than standard ones, aiming to give pathologists a clearer sample. Researchers will compare tissue amount and quality from both needles in 200 men with sus…
Sponsor: Uro-1 Medical • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
New blood test aims to sharpen prostate cancer detection
Diagnosis Recruiting nowThis study is testing a blood test called Proclarix to see if it can better identify men with aggressive prostate cancer before they have a biopsy. About 500 men aged 40-75 with certain PSA levels will give a blood sample before their scheduled biopsy. The test results will be co…
Sponsor: Sequenom, Inc. • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
Can repeated MRI scans reveal how tumors respond to radiation?
Diagnosis Recruiting nowThis study tests whether taking multiple MRI scans before, during, and after standard radiation therapy can help doctors see how tumors change. Researchers will enroll people with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer, or pediatric glioma. The g…
Sponsor: Dana-Farber Cancer Institute • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
Blood test may spot cervical cancer without a biopsy
Diagnosis Recruiting nowThis trial tests whether a simple blood test can help detect and monitor cervical cancer. Researchers will analyze tiny DNA fragments and particles in the blood, called cell-free DNA and extracellular vesicles, to see if they act as early warning signs. The study involves 100 wom…
Sponsor: Queensland Centre for Gynaecological Cancer • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
New blood test could spot 10 cancers before symptoms start
Diagnosis Recruiting nowThis study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…
Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
AI takes on radiologists in prostate cancer detection showdown
Diagnosis Recruiting nowThis study compares a new artificial intelligence (AI) system to radiologists for reading prostate MRI scans to detect cancer. About 130 men who are already scheduled for a prostate biopsy will have their MRI read by both the AI and a radiologist. The goal is to see if the AI can…
Sponsor: University of Southern California • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
New AI tool could spot hidden prostate cancer on MRI scans
Diagnosis Recruiting nowThis study tests a new software tool that automatically analyzes MRI images of the prostate to find cancer areas that doctors might miss. About 180 people with known or suspected prostate cancer will get an MRI and then a targeted biopsy. Researchers will compare the software's a…
Sponsor: University of Chicago • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
Could STI testing be the key to getting more women on HIV prevention?
Prevention Recruiting nowThis study in Uganda tests whether adding lab tests for common sexually transmitted infections (STIs) to standard HIV risk screening helps more women start and stick with PrEP, a daily pill that prevents HIV. About 4,500 HIV-negative women aged 15-39 will be randomly assigned to …
Sponsor: Johns Hopkins University • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
New model aims to eliminate HIV transmission from mothers to infants in malawi
Prevention Recruiting nowThis study is testing a new approach called PAC-Man to help prevent HIV from passing from mothers to their babies. About 2,426 mothers and infants in Malawi will take part. The goal is to see if this model helps more babies get tested for HIV early and ensures mothers receive pro…
Sponsor: University of North Carolina, Chapel Hill • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Monthly HIV prevention pill could replace daily dose
Prevention Recruiting nowThis phase 3 trial tests MK-8527, a once-monthly oral pill, to prevent HIV-1 infection in women. About 4580 HIV-negative women will take either MK-8527 monthly or a daily PrEP pill (Truvada) to see which works better and is safer. The goal is to offer a more convenient prevention…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Can a Three-Session couples program cut drug use and HIV risk?
Prevention Recruiting nowResearchers are testing whether a three-session couples motivational interviewing program helps male couples reduce illicit drug use and behaviors that raise HIV transmission risk. The trial enrolls 360 male couples where at least one partner is HIV negative and at least one has …
Sponsor: Hunter College of City University of New York • Aim: Prevention
Last updated Sep 19, 2026 00:00 UTC
-
Can a common antibiotic shield mothers and babies from infection?
Prevention Recruiting nowResearchers are testing whether giving the antibiotic zinacef during labor lowers infections for women with meconium-stained amniotic fluid at term and for their newborns. The trial enrolls 182 women with a single full-term pregnancy and meconium in the fluid. Half receive zinace…
Sponsor: Western Galilee Hospital-Nahariya • Aim: Prevention
Last updated Sep 17, 2026 00:00 UTC
-
New HIV prevention shot tested in real-world clinics
Prevention Recruiting nowThis study looks at how well people stick to a new HIV prevention shot called lenacapavir. About 3,000 people in the U.S. who want or need HIV prevention will take part. Researchers will track who stays on the shot and how it works in everyday clinic settings.
Sponsor: Gilead Sciences • Aim: Prevention
Last updated Sep 17, 2026 00:00 UTC
-
Can an HPV shot stop vulvar lesions from coming back?
Prevention Recruiting nowWomen treated for vulvar high-grade squamous intraepithelial lesion (vHSIL), a precancerous condition linked to HPV, often see it return. This trial tests whether giving the Gardasil 9 HPV vaccine alongside standard treatment (surgery, laser, or imiquimod) can lower that recurren…
Phase 4 • Sponsor: Erasmus Medical Center • Aim: Prevention
Last updated Sep 17, 2026 00:00 UTC
-
Could friendly bacteria in a gel stop HIV? new study begins
Prevention Recruiting nowThis early-stage study tests a vaginal gel containing specially modified bacteria that produce an anti-HIV drug. The goal is to see if it is safe for healthy women and whether it can be cleared with antibiotics. If successful, this could become a long-lasting, woman-controlled HI…
Phase 1 • Sponsor: Craig Cohen, MD, MPH • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC
-
Training police to refer, not arrest, could curb Drug-Related harm
Prevention Recruiting nowThis trial tests a police education program called SHIELD 2.0 in nine counties in Appalachian Kentucky. The program trains local behavioral health workers to teach police how to refer people who use drugs to treatment and social services instead of arresting them for low-level po…
Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC
-
Can a virtual promotora get more hispanic women screened for cervical cancer?
Prevention Recruiting nowResearchers at Florida A&M University are testing whether a virtual educational session led by a lay health advisor, called a promotora, helps Hispanic women who are behind on cervical cancer screening get tested. The trial enrolls about 160 Hispanic women ages 21 to 65 who have …
Sponsor: Florida A&M University • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC
-
Prisons as HIV prevention hubs: can opioid treatment reach more people behind bars?
Prevention Recruiting nowResearchers at Yale University are studying how to expand opioid agonist therapy (OAT) in prisons and probation systems in Tajikistan, Kyrgyzstan, Moldova, and Georgia. OAT uses medicines like methadone or buprenorphine to treat opioid dependence and can lower HIV transmission am…
Sponsor: Yale University • Aim: Prevention
Last updated Sep 12, 2026 00:00 UTC
-
New program aims to boost HIV prevention in pregnant women
Prevention Recruiting nowThis study tests a program called TENDAI4PrEP, which uses problem-solving techniques to help pregnant women in Zimbabwe take PrEP, a daily pill that prevents HIV. The program also involves their partners and healthcare providers. Researchers will enroll 132 HIV-negative pregnant …
Sponsor: Massachusetts General Hospital • Aim: Prevention
Last updated Sep 12, 2026 00:00 UTC
-
Can virtual reality curb substance use and HIV in traumatized youth?
Prevention Recruiting nowThis study is developing and testing a virtual reality tool to help young people aged 15-30 who have experienced trauma and are at risk for substance use and HIV. The goal is to see if the tool can reduce substance use and risky behaviors. Researchers are recruiting young men who…
Sponsor: Medical University of South Carolina • Aim: Prevention
Last updated Sep 11, 2026 00:00 UTC
-
New tool aims to boost HIV prevention in Women's health clinics
Prevention Recruiting nowThis study tests a decision aid that helps women in sexual and reproductive health clinics decide whether to take PrEP, a daily pill that prevents HIV. The tool will be used during counseling visits. Researchers will see if it increases PrEP use and if it's practical for clinics.…
Phase 2 • Sponsor: Yale University • Aim: Prevention
Last updated Sep 06, 2026 00:00 UTC
-
Can a Two-Pill HIV prevention strategy outsmart the virus?
Prevention Recruiting nowThis Phase 3 trial tests whether taking HIV prevention pills only around the time of sex can reduce the risk of HIV infection in men who have sex with men. Participants take either TAF/FTC or TDF/FTC, starting with a dose 2 to 24 hours before sex and another dose a day later. The…
Phase 3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Jail-Based program aims to cut HIV risk after release
Prevention Recruiting nowThis study tests a program in the Dallas County Jail that identifies people at high risk for HIV and offers them testing and education about PrEP, a daily pill that prevents HIV. A patient navigator helps interested individuals connect with PrEP providers after they are released.…
Sponsor: University of Texas Southwestern Medical Center • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Pre-Radiation pelvic therapy may ease pain and sexual issues for women with pelvic cancers
Symptom relief Recruiting nowThis study looks at whether adding pelvic floor physical therapy before standard radiation treatment can help reduce pain and sexual problems in women with cervical, vaginal, vulvar, uterine, or anal cancer. About 20 participants will receive education on using a vaginal dilator …
Sponsor: Indiana University • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Headband may ease withdrawal after cushing surgery
Symptom relief Recruiting nowThis study looks at how people recover from Cushing syndrome after surgery. Researchers want to understand what affects recovery and whether using a MUSE biofeedback headband can help ease withdrawal symptoms. The study will include 700 adults who are planning to have curative su…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can an old blood vessel drug shorten labour when waters break at term?
Symptom relief Recruiting nowWhen a woman's waters break at term but labour has not started, doctors often use oxytocin to get contractions going. This trial tests whether adding a single intravenous dose of papaverine, a drug that relaxes smooth muscle, helps oxytocin work faster. Two hundred women with ter…
Sponsor: Wolfson Medical Center • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a tiny patch tame period pain without drugs?
Symptom relief Recruiting nowResearchers are testing whether a thin, drug-free patch called the Jovi Patch can reduce menstrual pain and related symptoms. The patch contains conductive micro-metal particles and no medication, wires, or batteries. About 50 pre-menopausal women with moderate to severe menstrua…
Sponsor: Signal Relief • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Laser zaps prostate troubles without cutting
Symptom relief Recruiting nowThis study compares a new laser procedure (TPLA) to standard surgery (TURP) for men with urinary symptoms caused by an enlarged prostate. Researchers want to see if the laser works just as well, with possibly fewer side effects. About 80 men will take part.
Sponsor: Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New proton therapy aims to reduce bowel side effects in gynecologic cancer patients
Symptom relief Recruiting nowThis study is testing a precise type of radiation (proton beam) given to the pelvis after surgery for cervical, uterine, or endometrial cancer. The goal is to see if it causes fewer bowel side effects than standard radiation. About 25 adults who need pelvic radiation after surger…
Phase 2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
CBD may cut opioid need in advanced prostate cancer
Symptom relief Recruiting nowThis study tests whether cannabidiol (CBD) can reduce the need for strong painkillers (opioids) in people with end-stage prostate cancer that has spread and no longer responds to standard treatments. About 58 participants will receive either CBD or a placebo three times daily for…
Phase 2 • Sponsor: Regionshospital Nordjylland • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Tai chi via zoom tested as depression remedy for older HIV patients
Symptom relief Recruiting nowThis study tests whether doing tai chi/qigong over Zoom twice a week for 12 weeks can reduce depressive symptoms in people aged 50-75 living with HIV. About 326 participants will be randomly assigned to either tai chi or a health education class. Researchers will track mood, hear…
Sponsor: Florida International University • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New shorter radiation may ease side effects for cancer patients
Symptom relief Recruiting nowThis study tests if a newer, shorter course of radiation therapy (MH-ART) is as good as the standard longer course (CF-IMRT) for women who have had surgery for cervical or endometrial cancer. The goal is to see if the new approach causes fewer side effects and improves quality of…
Sponsor: Xiaorong Hou • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Smartwatch workouts aim to beat Post-Chemo fatigue
Symptom relief Recruiting nowThis study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…
Sponsor: Centre Antoine Lacassagne • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Shockwaves to the penis tested against erectile dysfunction
Symptom relief Recruiting nowResearchers are testing low-intensity shockwave therapy for men with erectile dysfunction who get little or no response from standard oral drugs like Viagra. The trial enrolls 40 men aged 30 to 80 who have had ED for at least six months. Half receive four weekly shockwave session…
Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Can extra numbing shots make prostate biopsies hurt less?
Symptom relief Recruiting nowThis study looks at whether adding local anesthesia (numbing medicine) during a prostate biopsy, while patients are already sedated, reduces pain after the procedure. About 800 men will take part. The goal is to see if this simple change can lower pain scores, cut down on painkil…
Phase 3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
New device aims to quiet overactive bladder in men
Symptom relief Recruiting nowThis study tests a device called the Axonics SNM System, which uses mild electrical pulses to calm the nerves that control the bladder. It is for men with overactive bladder, including those with urgency incontinence or frequent urination. The trial will enroll 150 men and track …
Sponsor: Axonics, Inc. • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Amazon plant put to the test against Cancer's relentless tiredness
Symptom relief Recruiting nowCancer treatment often leaves patients with a deep, lasting tiredness that few treatments can fix. Researchers are testing whether guarana, a caffeine-rich Amazonian plant, can reduce that fatigue and improve daily life. The study gives 60 people with breast, lung, colorectal, ce…
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Lower back nerve block tested to cut pain after fibroid surgery
Symptom relief Recruiting nowResearchers are testing whether a quadratus lumborum nerve block reduces pain after laparoscopic myomectomy, a surgery to remove uterine fibroids while keeping the uterus. The block is a temporary anesthetic injection into a lower back muscle. In this double-blind, randomized tri…
Phase 4 • Sponsor: Joseph Findley MD • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Could a simple alcohol injection ease endometrioma pain?
Symptom relief Recruiting nowThis study tests whether ultrasound-guided alcohol sclerotherapy can reduce pelvic pain and improve quality of life in women aged 18-45 with ovarian endometriomas. Participants are randomly assigned to receive the procedure or no treatment (expectant management) and are followed …
Sponsor: Hospital Universitari de Bellvitge • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
AI chatbot could help gynecologic cancer survivors reclaim sexual health
Symptom relief Recruiting nowResearchers in Taiwan are testing LillyBot, an AI chatbot that provides personalized sexual health education and consultation for women who have had gynecologic cancer. The trial will enroll 90 survivors and compare two versions of the system, one with proactive nurse contact and…
Sponsor: Chang Gung Memorial Hospital • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
New hope for endometriosis sufferers: drug trial targets pelvic pain
Symptom relief Recruiting nowThis study tests a new drug called vipoglanstat to see if it can reduce pelvic pain in people with endometriosis. About 190 women aged 18 to 44 with moderate to severe pain will take either the drug or a placebo for four months. The goal is to find a better treatment option for t…
Phase 2 • Sponsor: Gesynta Pharma AB • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Massage during chemo: a new way to ease cancer treatment stress?
Symptom relief Recruiting nowThis small study will test whether giving a 15-20 minute massage during infusion therapy can reduce pain and anxiety in women with gynecologic cancer. Twenty-four participants will be randomly assigned to receive either a hand, foot, or neck/shoulder massage or simply talk with t…
Sponsor: Jill Cole • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Tapping and music therapy tested to ease stress in High-Risk pregnancy
Symptom relief Recruiting nowThis study will test whether Emotional Freedom Technique (a type of tapping) and music therapy can reduce stress, anxiety, and depression in women with a high-risk pregnancy due to early rupture of membranes. About 177 women will be randomly assigned to receive these therapies or…
Sponsor: Selcuk University • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Progesterone boost may help IUI success
Symptom relief Recruiting nowThis study tests whether taking progesterone (a hormone) after intrauterine insemination (IUI) increases the chance of pregnancy in women who also took letrozole to stimulate their ovaries. About 690 women in Denmark will be randomly assigned to receive either progesterone vagina…
Phase 4 • Sponsor: Kirstine Kirkegaard • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can AI personalize exercise to ease pelvic pain?
Symptom relief Recruiting nowResearchers at Mount Sinai are testing whether a reinforcement learning system can deliver personalized daily exercise recommendations to people with chronic pelvic pain. The study enrolls 45 adults who receive alternating standard and AI-generated exercise advice over four two-w…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
New program aims to help HIV/TB patients kick the habit
Symptom relief Recruiting nowThis study is testing a new program called QUIT-AD to help people living with HIV or tuberculosis (TB) in Cape Town, South Africa, quit smoking. The program combines proven methods to support smoking cessation and improve HIV/TB treatment results. Researchers will enroll 86 daily…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Which cervical prep eases hysteroscopy for postmenopausal women?
Symptom relief Recruiting nowThis trial tests whether preparing the cervix with medication before office hysteroscopy helps postmenopausal women have a more successful and less painful procedure. Participants are randomly assigned to receive either oral misoprostol, vaginal estrogen for 7 or 14 days, or no p…
Sponsor: Faculty of Medicine of Tunis • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Could a tiny dose of naltrexone beat cancer fatigue?
Symptom relief Recruiting nowThis phase 2 trial tests whether a low dose of naltrexone (LDN) can reduce fatigue in men with prostate cancer who are on hormone therapy (ADT). The study will enroll 60 participants and measure fatigue, quality of life, and safety. It is not yet recruiting.
Phase 2 • Sponsor: University of Arkansas • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Magic mushroom therapy targets cancer fear in remission patients
Symptom relief Recruiting nowThis early-phase study tests whether psilocybin (the active ingredient in magic mushrooms) combined with talk therapy can reduce fear of cancer returning in 20 women with early-stage breast or ovarian cancer who are currently in remission. Participants receive a moderately high d…
Phase 1 • Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
New study monitors eye health in cervical cancer drug TIVDAK
Symptom relief Recruiting nowThis study looks at possible eye-related side effects in people with cervical cancer that has returned or spread, who are being treated with the drug TIVDAK. About 100 participants will receive TIVDAK every 3 weeks and undergo regular eye exams before, during, and after treatment…
Phase 4 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
New study tests if happiness skills can curb stimulant use in HIV patients
Symptom relief Recruiting nowThis study tests whether a 5-session online program teaching positive thinking skills can help people with HIV who use stimulants. Researchers want to see if it reduces stimulant use and depression by changing brain and immune function. 189 participants will be followed for 3 mon…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Could a simple supplement protect your gut during radiation?
Symptom relief Recruiting nowThis study tests whether taking a short chain fatty acid supplement can reduce gut-related side effects in people receiving radiation therapy for cancers in the abdomen or pelvis. About 122 adults will be randomly assigned to receive either the supplement or a placebo. The goal i…
Phase 1/2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Can stretching before surgery boost penile implant results?
Symptom relief Recruiting nowThis study tests whether using a penile traction device (RestoreX) for 3 months before getting a penile implant can increase the length of the implant and improve patient satisfaction. About 48 men with erectile dysfunction will be randomly assigned to use the device or not. The …
Sponsor: J. Peter Rubin, MD • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Laser therapy offers hope for breast cancer survivors suffering from vaginal dryness
Symptom relief Recruiting nowThis study tests a laser treatment for vaginal dryness in breast cancer survivors. Many survivors experience this side effect from cancer treatments like chemotherapy or hormone therapy. The trial will compare the laser to no treatment in 250 women to see if it improves symptoms.
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Can acupuncture needles help bladder recovery after cancer surgery?
Symptom relief Recruiting nowThis study looks at whether electroacupuncture (a type of acupuncture with mild electric pulses) can help women who have trouble urinating after surgery for cervical cancer. About 208 participants will receive either real or fake electroacupuncture alongside standard care. The ma…
Sponsor: Lu Chao • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
New group therapy aims to tame meltdowns in Prader-Willi teens
Symptom relief Recruiting nowThis study tests a group program to help teens (ages 13-17.5) with Prader-Willi Syndrome and their families learn practical ways to handle irritability, meltdowns, and anxiety. Ten participants will attend weekly 90-minute sessions. The goal is to see if the program improves emot…
Sponsor: Children's Mercy Hospital Kansas City • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Spring implant aims to ease prostate troubles in Real-World study
Symptom relief Recruiting nowThis study tracks how well the Zenflow Spring System works in everyday medical practice for men with BPH (enlarged prostate). About 300 participants will be followed for a year to see if symptoms improve, how quickly they return to normal activities, and if any side effects occur…
Sponsor: Zenflow, Inc. • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
A new program aims to ease cancer survivors' fear of recurrence
Symptom relief Recruiting nowThis trial tests a program that screens cancer survivors for fear of recurrence and refers those who need help to psychological services. The program is being rolled out in cancer clinics in Hong Kong, with nurses trained to identify at-risk patients. Researchers will measure how…
Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Ovarian Cancer's spread: scientists probe abdominal fluid for clues
Knowledge-focused Recruiting nowResearchers at the University of New Mexico collect ascites fluid, the liquid that builds up in the abdomen, from women undergoing surgery for ovarian cancer. They study this fluid and tumor tissue in the lab to learn how the tumor environment helps cancer spread within the perit…
Sponsor: New Mexico Cancer Research Alliance • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New trial uses DNA tests to match cancer patients to targeted drug cocktails
Knowledge-focused Recruiting nowThis large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists hunt for prostate cancer clues in tissue and blood samples
Knowledge-focused Recruiting nowThis study collects blood, urine, saliva, and tumor tissue from 3,000 men with prostate cancer to investigate genetic changes that cause the disease. Participants may also undergo imaging and answer quality-of-life questions. The goal is to better understand prostate cancer and l…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists map HIV's hiding spots in early infection
Knowledge-focused Recruiting nowResearchers want to understand how HIV builds a hidden reservoir in the body when someone starts treatment during the earliest stage of infection. The study follows 70 recently infected people who begin combination antiretroviral therapy right away. Over two years, participants g…
Sponsor: University Hospital, Ghent • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Blood platelets may hold clues to HIV's hidden hideouts
Knowledge-focused Recruiting nowThis study investigates whether platelets—tiny blood cells involved in clotting—interact with HIV-infected immune cells in ways that affect the virus's ability to persist despite treatment. Researchers will collect blood samples from 90 adults with HIV who have had undetectable v…
Sponsor: Tourcoing Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Decades of HIV data could reveal which treatments last
Knowledge-focused Recruiting nowResearchers follow people with HIV who took part in earlier HIV-NAT studies to see how their health changes over many years. The study collects information on treatment history, side effects, other illnesses, and lab results such as viral load and CD4 counts. By tracking a large …
Sponsor: The HIV Netherlands Australia Thailand Research Collaboration • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Pregnancy hormone hCG may hold clues to bone and gland health
Knowledge-focused Recruiting nowResearchers are studying whether blood levels of luteinizing hormone (LH) and human chorionic gonadotropin (hCG) are linked to the presence, severity, and long-term outcomes of endocrine disorders such as osteoporosis, thyroid disease, and adrenal gland problems. The study enroll…
Sponsor: Martin Blomberg Jensen • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
HIV hiding spots revealed in treatment pause study
Knowledge-focused Recruiting nowThis study aims to understand where HIV hides in the body when people stop their daily antiretroviral therapy (ART) for a short time. Fifty adults with HIV will either stay on ART or pause it for up to 90 days. Researchers will use PET/CT scans and take small tissue samples from …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
NIH launches major study to unravel hormone mysteries
Knowledge-focused Recruiting nowThis study at the National Institutes of Health is looking at 1,000 adults with known or suspected hormone gland (endocrine) disorders. The goal is to better understand these conditions and help train doctors. Participants may receive tests, treatments, or surgery as part of thei…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New study creates ovarian tissue databank to unlock fertility secrets
Knowledge-focused Recruiting nowThis study collects and stores ovarian tissue from females aged 4 to 35 who choose to freeze a sample before cancer treatment that could harm their fertility. Researchers will also gather medical data and annual surveys for up to 30 years. The goal is to build a national database…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists probe HIV's secret hiding spots in uganda
Knowledge-focused Recruiting nowThis study looks at HIV that stays hidden in the body even when the virus is under control. Researchers will measure the 'latent HIV reservoir' in 130 Ugandans with HIV and compare it to similar groups in the US. Participants give blood samples and answer health questions. No new…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists watch thyroid conditions unfold in 2,500 patients
Knowledge-focused Recruiting nowThis study follows up to 2,500 people with thyroid problems like hyperthyroidism, hypothyroidism, or Graves' disease. Researchers will track how these conditions develop over time using standard medical tests and genetic samples. The goal is to better understand the natural histo…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
HIV study aims to unlock mystery of Post-Treatment immune Flare-Ups
Knowledge-focused Recruiting nowThis study looks at why some people with HIV develop Immune Reconstitution Inflammatory Syndrome (IRIS) after starting HIV medications. Researchers will use PET scans and lymph node biopsies to track inflammation and immune recovery in 300 adults. The goal is to better understand…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Rare cancer syndrome under the microscope: what families need to know
Knowledge-focused Recruiting nowThis study follows people with a rare genetic condition called DICER1 syndrome, which raises the risk of certain childhood cancers like pleuropulmonary blastoma. Researchers will collect medical histories, genetic samples, and tissue from up to 1,500 participants and their relati…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists hunt for genetic clues in prostate cancer blood samples
Knowledge-focused Recruiting nowThis study collects blood samples from 1,000 men with prostate cancer to look for genetic differences that might explain why some cancers stop responding to hormone therapy. Participants give blood at clinic visits, and researchers analyze DNA and other genetic material. No treat…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists seek tissue samples to unlock HIV and cancer mysteries
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tissue samples from people with HIV, KSHV, or certain cancers to help researchers learn more about these diseases. Participants must be 18 or older and may have HIV, KSHV, or related conditions. No treatment is given; the goal is to gat…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists hunt for immune secrets behind HIV control
Knowledge-focused Recruiting nowThis study collects white blood cells and plasma from 400 people with HIV, including rare 'non-progressors' who control the virus without medication. Researchers will analyze immune responses and genetic markers to understand what makes these individuals special. The goal is to u…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists dive deep into HIV immune cells to unlock secrets of early treatment
Knowledge-focused Recruiting nowThis study collects white blood cells from HIV patients through a process called leukapheresis to examine how the immune system responds to early treatment. Researchers aim to enroll 60 adults—30 with early HIV and 30 with chronic HIV—who are not yet on antiretroviral therapy. Pa…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
NIH launches massive study to unlock HIV's secrets through blood
Knowledge-focused Recruiting nowThis study aims to learn more about how HIV infects cells and affects the immune system by collecting blood samples from up to 2,419 adults, both with and without HIV. Researchers will analyze these samples to compare genetic and protein differences. The goal is to better underst…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New MRI study aims to unlock secrets of prostate cancer recurrence
Knowledge-focused Recruiting nowThis study uses detailed MRI scans and targeted biopsies to investigate why some prostate cancers come back after radiation therapy. Researchers will follow 300 men who are scheduled for radiation or whose cancer has returned after earlier treatment. The goal is to better underst…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists launch Long-Term study to unravel mysterious liver disease
Knowledge-focused Recruiting nowThis study is observing 400 people aged 12 and older who have noncirrhotic portal hypertension (NCPH) or are at risk for it. NCPH is a liver condition that increases blood pressure in the liver's blood vessels without causing cirrhosis, and often has no early symptoms. Researcher…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Cured of cushing as a kid? scientists want to track your health for years
Knowledge-focused Recruiting nowThis study looks at the long-term health of people who were cured of Cushing disease before age 21. Researchers want to understand how past high cortisol levels affect the body and mind years later. Participants will complete surveys and have check-ups every 5 years. The goal is …
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Researchers seek blood donors to advance infectious disease science
Knowledge-focused Recruiting nowThis study collects blood plasma and white blood cells from healthy volunteers and people with HIV using a procedure called apheresis. The samples are used for laboratory research on infectious diseases and immune function. Up to 3,000 participants aged 18 and older will be enrol…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
What do women know about endometrial cancer? new study aims to find out
Knowledge-focused Recruiting nowThis study talks to women with and without endometrial cancer to learn what they know about risk factors and prevention options. Researchers hope to create a tool that helps women make informed decisions. About 45 women will take part at MD Anderson Cancer Center.
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
HIV memory mystery: even controlled virus may harm the brain
Knowledge-focused Recruiting nowThis study looks at why some people with HIV who have very low virus levels in their blood still develop thinking and memory problems. Researchers will follow 1,150 participants—including healthy volunteers—for up to 10 years, using brain scans, blood tests, and spinal fluid samp…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
DNA registry aims to decode how inherited genes shape prostate cancer
Knowledge-focused Recruiting nowThe PROMISE registry collects health information and saliva samples from people diagnosed with prostate cancer at any stage. Researchers test the samples for inherited gene variants that raise cancer risk and follow participants for at least 15 years. The goal is to learn how the…
Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New blood test could help guide prostate cancer treatment
Knowledge-focused Recruiting nowThis study is testing a new algorithm that uses a liquid biopsy (a simple blood test) to find HRR gene mutations in patients with metastatic prostate cancer. It is for patients whose tumor tissue is not available or is inadequate for standard testing. The goal is to see if this m…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
AI vs. radiologist: who spots prostate cancer better?
Knowledge-focused Recruiting nowThis study looks at whether artificial intelligence (AI) can help radiologists find prostate cancer on MRI scans. About 150 men aged 55-80 who are scheduled for a prostate biopsy will take part. The AI software will be compared to radiologists reading the scans alone. The goal is…
Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Sperm sorting showdown: can a microchip pick the best sperm for pregnancy?
Knowledge-focused Recruiting nowResearchers at the University of California, San Francisco, are comparing two ways to prepare sperm before intrauterine insemination (IUI). One method uses a microfluidic device called Zymot Multi to sort sperm, while the other uses density gradient centrifugation, a standard lab…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New scanner could help surgeons see cancer in removed tissue instantly
Knowledge-focused Recruiting nowThis study is testing a new PET-CT scanner that takes high-resolution images of tissue removed during cancer surgery. Researchers want to see if these images match lab results and help surgeons make better decisions. The study will include 850 people with prostate, breast, head a…
Sponsor: XEOS Medical • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New database aims to unlock secrets of metabolic radiotherapy
Knowledge-focused Recruiting nowThis study is creating a large database of medical information and blood samples from 350 adults receiving metabolic radiotherapy for thyroid, prostate, or neuroendocrine cancers. The goal is to provide researchers with valuable data to better understand these treatments. No new …
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Lab-Grown tumor models could match patients to the right cancer drug
Knowledge-focused Recruiting nowResearchers at University Hospital, Strasbourg, are developing 3D tumor models grown from patient tissue to study kidney, bladder, and prostate cancers. The study collects tumor samples and a small blood sample from about 100 adults with these cancers. Scientists use the blood to…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New european registry aims to unlock mysteries of rare breast disease
Knowledge-focused Recruiting nowThis study is creating a European registry for people with idiopathic granulomatous mastitis (IGM), a rare inflammatory breast condition that causes pain, redness, and abscesses. Researchers will collect information from 1,000 participants to better understand symptoms, treatment…
Sponsor: European Breast Cancer Research Association of Surgical Trialists • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can science predict cancer fatigue? new study seeks answers
Knowledge-focused Recruiting nowThis study tracks 125 cancer patients receiving standard chemotherapy and radiation to understand why they feel tired. Researchers will collect blood, stool, and survey data before, during, and after treatment. The goal is to find patterns that could help predict and manage fatig…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New study aims to determine if less surgery is better for Early-Stage endometrial cancer
Knowledge-focused Recruiting nowThis study looks at whether removing only a few key lymph nodes (sentinel node biopsy) is better than removing no nodes at all in women with early-stage endometrial cancer. The goal is to see if this approach helps women return to normal activities faster and does not increase th…
Phase 3 • Sponsor: Queensland Centre for Gynaecological Cancer • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Ovarian cancer test accuracy under review in 1,000 women
Knowledge-focused Recruiting nowThis study looks at how well different labs agree when testing for a protein called FRa in stored tumor samples from women with ovarian cancer. About 1,000 women's archived tissue will be tested, but no new treatments or visits are needed. The goal is to improve consistency of FR…
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
New registry aims to unlock secrets of rare cervical cancer
Knowledge-focused Recruiting nowThis study is creating a registry of 750 people with a rare and aggressive form of cervical cancer called neuroendocrine carcinoma. Researchers will collect information from medical records to learn more about the disease, how it is treated, and what happens to patients over time…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Could saving a tiny artery prevent deadly leaks after colon surgery?
Knowledge-focused Recruiting nowThis study looks at whether preserving the left colic artery during colon or rectal cancer surgery helps keep the remaining colon well-supplied with blood. Surgeons will temporarily clamp the main artery and use a green dye to measure blood flow. The goal is to see if this techni…
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Scientists launch major study to track viruses in healthy and immunocompromised patients
Knowledge-focused Recruiting nowThis study aims to collect samples and medical information from people of all ages who have or have been exposed to viral infections, including COVID-19 and herpes. Researchers want to understand how viruses affect healthy individuals versus those with weakened immune systems. Pa…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Can a smartwatch track how kids recover from cancer surgery?
Knowledge-focused Recruiting nowThis study is testing whether smartwatches and blood tests can measure how well children recover after surgery to remove a solid tumor. About 40 children and their caregivers will wear smartwatches and answer questionnaires before surgery and for up to a year after. Researchers w…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Massive Real-World database aims to map how chronic diseases interact
Knowledge-focused Recruiting nowOPERA is a large observational database that collects health records from people treated for chronic conditions such as HIV, liver disease, inflammatory bowel disease, heart disease, rheumatic disease, and neurodegenerative disease. Researchers use the records to study how these …
Sponsor: Epividian • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Can a better scan spot hidden prostate cancer?
Knowledge-focused Recruiting nowThis study is testing whether two types of PET scans can better detect where prostate cancer has spread in the body. About 300 men with prostate cancer that is getting worse will receive injections of a radioactive tracer and then be scanned. The goal is to see if these scans are…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Can ultrasound and tissue clues reveal which endometriosis lesions carry cancer risk?
Knowledge-focused Recruiting nowResearchers are studying atypical endometriosis, a form of the condition whose cells look unusual under the microscope and may sometimes precede ovarian cancer. The study enrolls about 200 adults scheduled for endometriosis surgery or surgery for suspected ovarian or endometrial …
Sponsor: Casa di Cura Dott. Pederzoli • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Timing matters: study probes catheter use before prostate surgery
Knowledge-focused Recruiting nowThis study looks at men with urinary retention who need a catheter before having prostate laser surgery (HoLEP, ThuLEP, or ThuFLEP). Researchers want to see if the length of time with a catheter affects how well the surgery works. They will measure changes in urinary symptoms, fl…
Sponsor: Eskişehir Osmangazi University Medicine Faculty Hospital • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Blood test may personalize ovarian cancer care after surgery
Knowledge-focused Recruiting nowThis study is testing whether a blood test that looks for tiny bits of tumor DNA (called ctDNA) can help doctors decide who needs extra treatment after ovarian cancer surgery. Researchers will analyze stored blood samples from 50 patients taken before and after surgery. The goal …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Could your DNA hold the key to preventing hearing loss?
Knowledge-focused Recruiting nowThis study aims to understand why people with Turner syndrome often lose their hearing. Researchers will look at genetic and epigenetic markers in 150 adults aged 18-60. Participants will have hearing, balance, blood, and imaging tests. The goal is to find new ways to treat or de…
Sponsor: Gødstrup Hospital • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
HIV pain puzzle: are natural painkillers to blame?
Knowledge-focused Recruiting nowThis study looks at whether people with HIV have chronic pain because their bodies don't make enough natural painkillers (opioid peptides). Researchers will test pain sensitivity in 200 adults (with and without HIV) using heat, touch, and pressure. The goal is to understand the c…
Sponsor: Florida International University • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Scientists hunt for genetic clues in Virus-Linked cancers
Knowledge-focused Recruiting nowThis study collects tissue and blood samples from adults with HIV, other immune disorders, or cancers thought to be caused by viruses. Researchers will compare genes in cancer tissue to normal tissue to find genetic changes that drive these cancers. The goal is to better understa…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Robotic prostate surgery may raise eye pressure, new study warns
Knowledge-focused Recruiting nowThis study looks at how the head-down position and gas used during robotic prostate surgery affect pressure inside the eye. Researchers will measure eye pressure with a simple ultrasound in 50 men having either robotic or open prostate surgery. The goal is to understand these cha…
Sponsor: Ege University • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
700 men with prostate cancer to help shape future treatments
Knowledge-focused Recruiting nowThis study will follow 700 men with high-risk localized or metastatic prostate cancer to collect detailed information on how they are treated in everyday practice. Researchers will track treatments, side effects, quality of life, and disease progression over time. The goal is to …
Sponsor: Radboud University Medical Center • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Could a simple dye replace major surgery for ovarian cancer staging?
Knowledge-focused Recruiting nowThis study looks at whether a blue dye injected into the ovary can help doctors find the first lymph node where cancer might spread, instead of removing many lymph nodes. The goal is to see if this less invasive method works as well as standard surgery for early-stage ovarian can…
Sponsor: Faculty of Medicine of Tunis • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Could freezing sperm outsmart father time?
Knowledge-focused Recruiting nowResearchers at IVI Murcia are studying whether freezing sperm can preserve its quality and molecular features that may decline with age. Men aged 18 to 65 provide a semen sample and a blood sample. Each semen sample is split into fresh, slow-frozen, and vitrified portions. The te…
Sponsor: IVI Murcia • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Robot-Assisted GYN surgery under the microscope: new study tracks Real-World outcomes
Knowledge-focused Recruiting nowThis study is observing how well robotic-assisted surgery works for women with gynecological conditions. It will follow 1,250 participants in Germany for up to 12 months after surgery to track complications, recovery, and patient-reported outcomes. The goal is to gather real-worl…
Sponsor: Intuitive Surgical • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Stress and your cycle: new study investigates the link
Knowledge-focused Recruiting nowThis study looks at how non-food-related stressors (like work or emotional stress) affect menstrual health in pre-menopausal women. Researchers will measure stress hormones and sex hormones in 600 women over 6 months. The goal is to understand if stress directly causes menstrual …
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Cancer diagnosis can shock the whole family: study maps who struggles most
Knowledge-focused Recruiting nowResearchers at Lille University are following 350 people, including cancer patients recently diagnosed with breast, gynecological, testicular or digestive cancer, their caregivers, and healthcare professionals. Over one year, participants answer questionnaires about post-traumati…
Sponsor: Lille University • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Could pollution and sleep habits be messing with your hormones? new study investigates.
Knowledge-focused Recruiting nowThis study looks at how things in your environment—like pollution, chemicals, diet, and sleep—might affect your hormones and reproductive health. Researchers will follow 300 people aged 8 and older who have conditions like low or high hormone levels, early or late puberty, or inf…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Researchers launch major study to unravel mysteries of excess male hormones
Knowledge-focused Recruiting nowThis natural history study aims to gather information from up to 3,000 people with genetic conditions that cause too much androgen (male-like hormones), such as congenital adrenal hyperplasia (CAH) and familial male-limited precocious puberty (FMPP). Participants undergo various …
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
10,000 men join quest to decode prostate cancer through scans
Knowledge-focused Recruiting nowThis study is gathering medical records and imaging data from 10,000 men with prostate cancer or at high risk. Researchers aim to find patterns in scans that could help diagnose and treat the disease more effectively. No new drugs or procedures are being tested.
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Can protein patterns in stored tumors point to new treatment targets?
Knowledge-focused Recruiting nowThis observational study in Vietnam looks at archived tumor samples from patients with several solid cancers, including liver, colorectal, gastric, breast, lung, endometrial, melanoma, and pancreatic cancer. Researchers will measure the presence of two proteins, ENPP1/cGAS and FA…
Sponsor: Tam Anh Research Institute • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Scientists hunt for genetic clues behind childhood pituitary tumors
Knowledge-focused Recruiting nowThis study aims to uncover the genetic causes of pituitary and hypothalamic tumors in children. Researchers will collect blood and tumor samples from up to 2,000 participants to analyze DNA and look for inherited patterns. The study also trains doctors and tests new MRI technique…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
500 women with advanced uterine cancer to have tumors genetically profiled
Knowledge-focused Recruiting nowThis study looks at the genetic makeup of advanced endometrial cancer in 500 women in Russia. Researchers will test tumor samples for specific gene changes to see how common they are and what treatments patients receive. The goal is to gather information, not to test a new treatm…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Can a blood bank unlock the secrets of HIV control?
Knowledge-focused Recruiting nowThis observational study enrolls 2,500 people with HIV to build a detailed bank of blood samples and health records. Researchers will use these specimens to investigate how the virus behaves, why some people progress slowly or control the virus without medication, and how antiret…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Can estrogen protect hearts in early menopause? new study aims to find out
Knowledge-focused Recruiting nowThis observational study will follow 45 women with primary ovarian insufficiency (POI)—a condition that causes early menopause—who are starting estrogen replacement therapy. Researchers will measure heart health markers before and after 6 months of treatment and compare them to h…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
New study aims to unlock secrets of advanced prostate cancer
Knowledge-focused Recruiting nowThis study is collecting blood, urine, tissue samples, and health information from 300 men with advanced prostate cancer. Researchers hope to build a resource that will help them learn more about the disease and improve future care. Participants will not receive any experimental …
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Can a simple ultrasound predict outcomes in sick Moms-to-Be?
Knowledge-focused Recruiting nowThis study uses ultrasound to measure muscle, fat, and fluid changes in 121 critically ill pregnant or gynecological patients in the ICU. The goal is to see if these body composition changes are linked to serious outcomes like death, need for a breathing machine, or longer hospit…
Sponsor: Ain Shams University • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Why does Doxy-PEP fail some people? new study aims to find out
Knowledge-focused Recruiting nowThis study looks at why the antibiotic doxycycline, when taken after sex, prevents bacterial STIs in some people but not others. Researchers will measure doxycycline levels in hair, blood, and urine from 48 volunteers to develop better ways to track if people are taking the medic…
Early phase 1 • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New study gathers key materials to create personalized cell therapies for tough cancers
Knowledge-focused Recruiting nowThis observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Brazilian study maps HER2 in Women's cancers to guide future treatments
Knowledge-focused Recruiting nowThis study will test tumor samples from 350 adults with gynecological cancers (endometrial, ovarian, cervical, vulvar, and vaginal) to see how often they have high levels of the HER2 protein. Researchers will use two standard lab tests to measure HER2. The goal is to learn how co…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
At-Home swab could spot uterine cancer in lynch syndrome patients
Knowledge-focused Recruiting nowThis study explores whether people with Lynch syndrome can use a self-collected vaginal swab at home to detect early signs of uterine cancer. Researchers will enroll 30 participants who will collect samples and answer surveys. The main goal is to see if this approach is practical…
Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Can discarded ovarian tissue reveal how childhood conditions shape future fertility?
Knowledge-focused Recruiting nowThis study collects discarded ovarian tissue from girls aged 0 to 18 who are having surgery on their ovary for conditions like cysts or torsion. Researchers will examine the tissue to count follicles at different stages and compare them across ages and conditions. The goal is to …
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Can a TB infection leave a mark on the placenta?
Knowledge-focused Recruiting nowResearchers in Ethiopia are studying whether tuberculosis infection changes how the placenta develops and works. They will enroll 500 pregnant women at delivery clinics and use a blood test to identify those with TB infection. The team will compare placental tissue and infant out…
Sponsor: Lund University • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Can genes predict prostate cancer? new study follows High-Risk men
Knowledge-focused Recruiting nowThis study tracks 500 men aged 30-75 who have specific genetic changes linked to prostate cancer but have not been diagnosed. Researchers will monitor their health over time using yearly exams, blood tests, and MRI scans to understand how these genes affect cancer risk. The goal …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Navigating hope: study tests whether patient guides boost trial enrollment for cancer patients
Knowledge-focused Recruiting nowThis study compares two levels of patient navigation—high-intensity versus low-intensity—to see which helps more people with prostate or kidney cancer enroll in clinical trials. About 90 participants will be randomly assigned to receive either extra support from a patient navigat…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Brazil launches major study to map ovarian cancer treatment gaps
Knowledge-focused Recruiting nowThis observational study will look at how ovarian cancer is currently treated in Brazil, including surgeries, chemotherapy, and genetic testing. Researchers will collect data from 250 patients to find what is working well and what needs improvement. The goal is to use these insig…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
2000 volunteers help create a gold standard for cancer blood tests
Knowledge-focused Recruiting nowThis study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Can we tell which prostate cancers are dangerous? new study aims to find out.
Knowledge-focused Recruiting nowThis study follows 3,000 men with early-stage prostate cancer who have chosen active surveillance (close monitoring instead of immediate treatment). The goal is to discover biological markers that can tell apart aggressive cancers from slow-growing ones. Researchers hope this wil…
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
AI-Guided radiation may shield ovaries in young cancer patients
Knowledge-focused Recruiting nowThis study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Can orgasm trigger altered states of consciousness? a massive survey investigates
Knowledge-focused Recruiting nowThis study uses an online questionnaire to gather information from 15,000 Spanish-speaking adults about their sexual health, behaviors, and any experiences of altered consciousness during orgasm. The goal is to better understand the range of sexual function and pleasure, and to e…
Sponsor: Menoclinica by Palacios • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Scientists launch Decade-Long watch on kaposi sarcoma
Knowledge-focused Recruiting nowThis study follows 150 adults with Kaposi sarcoma (KS) for up to 10 years to learn how the disease behaves, why it comes back, and how it affects the immune system and organs. Participants will have regular check-ups, scans, and biopsies, but no new treatments are being tested. T…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
New sperm-boosting method tested in 300 men
Knowledge-focused Recruiting nowThis study tests a new lab technique called HyperSperm to see if it can make sperm move better and stay healthy. Researchers will collect semen samples from 300 men with different fertility issues and compare the new method to the standard one. The goal is to find a safer and mor…
Sponsor: Fecundis Lab SL • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Tiny coil placed inside nose could help surgeons spot hidden brain tumors
Knowledge-focused Recruiting nowThis study tests a small MRI coil placed inside the sphenoid sinus during pituitary tumor surgery. The goal is to see if it can provide clearer images of tiny tumors that standard MRI often misses. About 70 adults with pituitary tumors will take part. The coil is inserted through…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Researchers launch major tissue bank to unlock secrets of mesothelioma
Knowledge-focused Recruiting nowThis study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Can faith help women navigate menopause? a study looks for answers
Knowledge-focused Recruiting nowThis study asks whether the severity of menopausal symptoms and beliefs in sexual myths are linked to how strongly women hold intrinsic religious orientation. Researchers will survey healthy women aged 49 to 59 who have gone through menopause, using questionnaires to measure symp…
Sponsor: KTO Karatay University • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
New imaging study aims to unlock secrets of prostate cancer drug resistance
Knowledge-focused Recruiting nowThis study uses special PET/CT scans to see how advanced prostate cancer becomes resistant to newer hormone therapies like enzalutamide or abiraterone. Researchers will track changes in cancer lesions over time in 25 participants. The goal is to better understand resistance patte…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
No treatment, just samples: new study aims to understand cancer immunity
Knowledge-focused Recruiting nowThis study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Scientists launch major study to unravel mysteries of rare brain infection PML
Knowledge-focused Recruiting nowThis study follows 700 people with progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus. Researchers will collect blood, spinal fluid, and brain scans over time to understand how the disease progresses. No treatment is given; the goal is…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
AI may predict which pelvic floor therapy works best
Knowledge-focused Recruiting nowThis study will follow 1,360 Chinese women with pelvic floor disorders, such as postpartum weakness or mild to moderate prolapse, as they receive one of three rehabilitation treatments: pelvic floor muscle training, biofeedback electrical stimulation, or magnetic stimulation. Res…
Sponsor: Mingfu Wu • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can treating a hidden hormone problem after brain injury restore quality of life?
Knowledge-focused Recruiting nowThis study looks at adults who had a traumatic brain injury at least a year ago. Researchers want to see whether those with growth hormone deficiency have worse quality of life, fatigue, mood, and sleep than those without it. Participants complete questionnaires and a test for gr…
Sponsor: University of Calgary • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
New study sheds light on pregnancy challenges in rare adrenal disorder
Knowledge-focused Recruiting nowThis study looks at how women with a severe form of congenital adrenal hyperplasia (classic 21-hydroxylase deficiency) become pregnant and what happens during their pregnancies. Researchers will collect information from medical records and phone interviews with 200 adult women. T…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC